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Abstract
Bioinformatics has become an essential component of biology. With the advent of
high throughput technologies, interdisciplinary research areas such as life science in-
formatics/computational biology and system biology have emerged. The development
in these disciplines fundamentally transformed the way we study molecular biology.
Analysis of microarray and next generation sequencing (NGS) data is a trending topic
in the area. It requires more computational power and expertise than conventional
techniques. Therefore, data analysis and bioinformatics are integral parts of every
microarray/NGS base-study.
In this thesis, I focused on developing and performing integrative bioinformatic ap-
proaches to mine microarray and NGS data in the hematopoietic system. Haematopoie-
sis, the formation of blood cells from hematopoietic stem cells (HSC), is a well-studied
differentiation system. However, the molecular mechanisms underlying the develop-
ment and differentiation of antigen presenting dendritic cells (DC) remain unclear.
To investigate the molecular events in the course of HSC differentiation into DC,
comparative analysis of DNA microarray data of HSC, DC progenitor and DC were
performed to characterize the lineage-specific transcription programs. Accordingly,
many known and novel DC specific genes were identified. This study also uncovered
that common DC progenitors (CDP) acquire a DC-primed expression profile. In ad-
dition, the analysis of transforming growth factor beta 1 (TGF-β1) signaling reveals
that TGF-β1 acts on DC bifurcation point and directs conventional DC (cDC) subset
specification, at the expense of plasmacytoid DC (pDC) development.
Epigenetic modifications and transcription factor binding control gene expression. To
understand the regulatory mechanism in DC fate decision, a comprehensive genome-
wide chromatin map of DC development was generated by chromatin immunoprecip-
itation sequencing (ChIP-seq), including PU.1, H3K4me3, H3K9me3, H3K27me3. A
stage-to-stage epigenetic regulatory framework (MPP-CDP-cDC/pDC), which drives
DC commitment and specification, was constructed and thoroughly examined. Fur-
thermore, an integrative approach was developed to determine the DC regulatory
circuitry that elucidate the basic architecture and dynamics of transcriptional regula-
tion during DC development.
DNA methylation (DNAm) plays a crucial role in hematopoietic differentiation and
aging of organisms. It also provides a new perspective for biomarker selection. In this
thesis, a computational approach was developed to analyze a large collection of publicly
available genome-wide DNAm profiles of blood samples. A panel of age related CpG
sites was identified, that allows to predict human age. An Epigenetic-Aging-Signature
was further developed and verified, which only requires measurement of DNAm levels
at three CpG sites for age prediction.
The DNA de novo methyltransferase DNMT3A establishes the pattern of DNA methy-
lation. Many patients with acute myeloid leukemia (AML) have mutations in the ge-
netic sequence of DNMT3A, leading to a poor prognosis. To understand the epigenetic
modification of DNMT3A, a systematic analysis was conducted on the basis of pub-
licly available AML patient dataset from the Cancer Genome Atlas Research Network
(TCGA). Several aberrant hypermethylation regions at an internal promoter region
of DNMT3A were identified. These epimutations in DNMT3A were observed in AML
patients with significantly shorter event-free survival and overall survival, indicating
epigenetic modifications in the DNAm pattern mimic genetic mutations and can be
used as biomarkers.
Zusammenfassung
Die Bioinformatik ist als ein wichtiges Teilgebiet der Biologie inzwischen gut etabliert.
Durch den Einsatz von Hochdurchsatztechnologien entstanden interdisziplina¨re Forsch-
ungsbereiche, wie die computergestu¨zte Biologie und die Systembiologie. Diese Diszi-
plinen haben die Art und Weise, wie wir molekularbiologische Mechanismen erforschen,
von Grund auf vera¨ndert. Die Analyse von microarray und next generation sequencing
(NGS) Daten sind aktuelle Themen in der Bioinformatik. Dafu¨r wird deutlich mehr
Rechnerleistung und Fachkompetenz als bei gewo¨hnlichen Techniken beno¨tigt. Daher
ist die Bioinformatik und die Auswertung der so gewonnenen Daten fester Bestandteil
eines jeden microarray und NGS Experiments und. In dieser Arbeit habe ich einen
bioinformatischen Ansatz entwickelt, um microarray und NGS Daten des ha¨matopoet-
ischen Systems auszuwerten. Die Ha¨matopoese beschreibt die Bildung von Blutzellen
aus ha¨matopoetischen Stammzellen (hematopoietic stem cells, HSC) und ist ein sehr
gut erforschtes Stammzell- und Differenzierungssystem. Jedoch sind die molekularen
Mechanismen, die der Entwicklung und Differenzierung von dendritischen Zellen (den-
dritic cells, DC) zu Grunde liegen, bisher wenig erforscht.
Um die molekularen Ereignisse der Stammzelldifferenzierung in DC zu untersuchen,
wurden microarray Daten von HSC, DC Vorla¨uferzellen und DC verglichen, so dass
das spezifische Transkriptionsprogramm eines jeden Zelltyps charakterisiert werden
konnte. Dabei wurden bekannte aber auch neue DC spezifische Gene identifiziert.
Ebenfalls wurde gezeigt, dass DC Vorla¨uferzellen (common dendritic cell progenitor,
CDP) ein auf die DC Differenzierung vorbereitetes geprimtes Expressionsprofil haben.
Außerdem wurde nachgewiesen, dass die Differenzierung in die verschiedenen DC Sub-
typen durch den transforming growth factor β1 (TGF-β1) gesteuert wird. TGF-β1
beeinflußt insbesondere die Spezifizierung in klassische DC (classical DC, cDC).
Epigenetische Vera¨nderungen und die Bindung von Transkriptionsfaktoren kontrol-
lieren die Genexpression. Um die Regulationsmechanismen wa¨hrend der Entwicklung
der verschiedenen DC Subtypen zu bestimmen, wurde eine genomweite Chromatin-
analyse fu¨r den Transkriptionsfaktor PU.1 und die Histonmodifikationen H3K3me3,
H3K9me3 und H3K27me3 mittels chromatin immunoprecipitation und DNA Sequen-
zierung (ChIP-seq) durchgefu¨hrt. Es wurde ein Modell der epigenetischer Regulation
der DC Entwicklung erstellt, das die Festlegung und Spezifizierung von DC beschreibt
(MPP-CDP-cDC/pDC). Des Weiteren wurden DC Regelkreise identifiziert, die die Hi-
erarchie und Dynamik der Transkriptionsregulation in DC zu beschreiben.
Die DNA Methylierung (DNAm) spielt eine wichtige Rolle in der ha¨matopoetischen
Differenzierung und bei Alterungsprozessen, und bietet neue Mo¨glichkeiten zur Identi-
fizierung von Biomarker. In dieser Arbeit wurde ein computergestu¨tzter Algorithmus
entwickelt, um eine große Kollektion genomweiter DNA Methylierungsprofile aus Blut-
proben auszuwerten. Es wurden altersabha¨ngiger CpG Stellen identifiziert, mit denen
das menschliche Alter bestimmt werden kann. Daraus wurde ein epigenetisches Al-
terungsmuster abgeleitet, mit dem das Alter an Hand der Methylierungsprofile von
nur drei CpG Stellen vorhergesagt werden kann.
Die DNA de novo Methyltransferase DNMT3A ist fu¨r die DNA Methylierungen ve-
rantwortlich. Viele Patienten, die an akuter myeloischer Leuka¨mie (AML) leiden,
weisen Mutationen im DNMT3A Gen auf, was mit einer sehr schlechten Prognosen
fu¨r diese Patienten verbunden ist. Um die Bedeutung epigenetischer Vera¨nderun-
gen im DNMT3A Gen zu verstehen, wurden Daten von AML Patienten des Cancer
Genome Atlas Research Network (TCGA) systematisch untersucht. Es konnten hy-
permethylierte Regionen im internen DNMT3A Promotor identifiziert werden. Solche
Epimutationen wurden insbesondere in AML Patienten mit einer signifikant schlechteren
U¨berlebensrate gefunden. Das zeigt, dass epigenetische Modifikationen im DNA Methy-
lierungsmuster a¨hnliche Konsequenzen wie genetische Mutationen haben ko¨nnen und
daher auch als Biomarker eingesetzt werden ko¨nnen.
Chapter 1
Introduction
1.1 Transcriptome Mining by DNA Microarray
1.1.1 Core Principle of Microarray Assay
The invention of microarray technology almost 20 years ago revolutionized the way
biologists study the gene expression (Allison et al., 2006; Rung and Brazma, 2013).
Using spotting oligonucleotide probes at a high density glass or nylon arrays, one mi-
croarray detects the expression of thousands, even entire genome genes, simultaneously
(Rung and Brazma, 2013). Compared to traditional techniques like RT-PCR, which
are not applicable for a genome-wide survey, microarray is highly attractive because it
is comprehensive and does not rely on investigators to drive the experimental design
that might potentially lead to bias (Schuldt et al., 2011).
The fundamental principle of microarray technology is the complementary hybridiza-
tion between two strands of nucleic acids (Lockhart et al., 1996; Schena et al., 1995).
A DNA microarray is usually a solid support with thousands of oligonucleotide probes
attached. These probes are short sequences corresponding to known RNA species,
and typically used to estimate the abundance of the fluorescently labeled RNA that
are present in the investigated samples. When the labeled sample is subjected to a
microarray, a high-resolution fluorescent scanner is used to measure the fluorescent sig-
nal of hybridized RNA at each probe, which is reported as intensity. Probe intensity
corresponds to the transcription abundance of a particular gene. Current microarrays
harbor probes of all annotated genes in human or mouse genomes, therefore providing
as a sound basis for transcriptome profiling of investigated samples.
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Nowadays, microarray technology serves as a valuable tool in molecular biology and
system biology, which is not only used for expression analysis but also applied for
genome-wide genotyping, large-scale single nucleotide polymorphism (SNP) analysis,
copy number analysis and epigenetic modification analysis.
1.1.2 Gene Expression Microarray
The most popular application for microarray-based technology is measuring genome-
wide gene expression levels. Various manufactures, such as Affymetrix, Agilent and
Illumina, provide the genome-wide gene expression microarray platforms. Gene arrays
from Affymetrix and Agilent use short oligonucleotides to probe gene expression levels
in an RNA sample. Illumina takes a different approach called BeadArray Technology,
which is based on 3-micron silica beads. Each bead contains millions of copies of a
specific oligonucleotide that act as the capture sequences. With the advance of the
fabrication techniques, more probes can be incorporated in a single array allowing
the accurate estimation of gene expression levels. Affymetrix GeneChip platform, for
example, has been evolved from 3’ IVT expression array (i.e., Mouse Expression Set
430) to Whole-Transcript expression array (i.e. Mouse Exon ST Array). The number
of probes per array increased over 100-fold, from the former (45,000 probes) to the
latter (5,500,000 probes, Figure 1.1.1).
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Figure 1.1.1: The probe designs of Id2 gene in Affymetrix GeneChip plat-
forms.
MOE430 array includes 3 probesets for detecting Id2 expression, whereas Exon ST1
Array uses more probesets for the measurement.
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The Zenke lab used Affymetrix GeneChip array for transcriptional profiling already
at the end of nineties and their submission to ArrayExpress, one of the two major
repositories for microarray data sets, receives accession No. 1 and 2 (E-MEXP-1 and
E-MEXP-2; Hacker et al. 2003).
1.1.3 DNA Methylation Microarray
DNA methylation is crucial for myriad cellular processes, such as differentiation, aging
and malignant transformation, and represents one of the most widely studied epige-
netic modifications in human (Koch et al., 2012; Suzuki and Bird, 2008; Teschendorff
et al., 2009). Cytosine DNA methylation typically occurs in the sequence context of
CpG dinucleotides (CpGs; CpG sites). Throughout the genome CpG sites are rare,
whereas short regions with an exceptionally high frequency of CpGs (i.e. > 0.6) exist,
referred to as CpG islands (CGIs). In human, CGIs associate with approximately 60%
of gene promoter regions and most of them are in an unmethylated state (Portela and
Esteller, 2010). Changes in the methylation level of the promoter-associated CpGs or
CGIs can result in either gene silencing or activation. Frequently, DNA methylation
in promoter regions is associated with down-regulation of gene expression. In cancer
cells, tumor-suppressor genes are often hypermethylated in their promoter regions and
the gene expression is switched off (Shenker and Flanagan, 2012; Ushijima, 2005).
Recent studies indicate that DNA methylation is also involved in aging of organisms
(Koch et al., 2011; Schellenberg et al., 2011).
Microarray and next-generation sequencing-based technologies allow analysis of DNA
methylation at single base resolution or enrichment of methylated DNA regions (Beck,
2010; Laird, 2010). The conventional technique for assessing DNA methylation is based
on sodium bisulfite conversion. In the presence of bisulfite, unmethylated cytosines
of genomic DNA are chemically deaminated to uracil, while methylated cytosines are
resistant to bisulfite treatment and remain cytosine. Illumina Infinium Methylation
Assay is the most widely used array-based methylation profiling platform. Applying
the same principle as the conventional method, Illumina Infinium HumanMethyla-
3
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tion27 BeadChip detects the DNA methylation status of 27,578 CpG sites throughout
the genome in a single experiment. The interrogated CpG sites cover the promoter
regions of 14,475 genes, including nearly 13,000 well-annotated genes in the NCBI
CCDS Database (Genome Bulid 36) and over 1000 cancer-related genes or targets.
In addition, a total of 110 CpG sites located within miRNA promoter regions are
present on the array. For an individual CpG site, a pair of bead-bound probes is used
to detect the presence of T (unmethylated state) or C (methylated state). The beta
value, which is a quantitative measurement of the methylation level of a single CpG
site, is subsequently determined by calculating the ratio of the fluorescent intensities
of the methylated probe (M) and unmethylated probe (U) according to the following
formula:
Beta =
Max(M, 0)
Max(M, 0) +Max(U, 0) + 100
Here, Max(M, 0) and Max(U, 0) indicate the maximum value between M and 0, U and
0, respectively. The number 100 in the denominator is a constant offset to standardize
beta values when both methylated and unmethylated probe intensities are low. The
beta value, ranging from 0 (completely unmethylated) to 1 (completely methylated),
relates to the percentage of methylation for a given CpG site.
A major limitation of HumanMethlyation27 BeadChip is that most interrogated CpG
sites are located in the gene promoter regions. However, methylation across genes and
the role of the CpG sites in the intragenic or gene body regions have recently attracted
considerable interest (Shenker and Flanagan, 2012). Therefore, HumanMethylation450
BeadChip was developed to measuring over 450,000 CpG sites distributed across the
gene promoter regions, 5’ untranslated region (5’ UTR), first exon, gene body, and 3’
UTR, providing the higher resolution for understanding epigenetic changes.
1.1.4 Mining Microarray Data
Microarray experiments are often designed to answer key questions. Is gene A ex-
pressed in stem cells? Is gene B more expressed in a certain cell type than the other
4
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cell types? Can we use microarray data to classify samples derived from healthy indi-
viduals and patients? To answer these questions, we need to devise a good strategy
and to select or design novel bioinformatics tools. However, microarray analysis faces
various challenges, such as low number of replicates, measurement noise and uncon-
trolled biological factors. In addition, when testing a large number of hypotheses in
microarray experiments, it is inevitable that spurious patterns are detected by pure
chance. Despite these problems, there is a growing consensus on how analytic tools
can be used (Allison et al., 2006). In general, the analysis of microarray data includes
the following five steps: (1) data preprocessing, (2) exploratory analysis, (3) inferential
statistics, (4) various downstream bioinformatics analysis and (5) validation.
The first step of microarray analysis is data preprocessing, which is relevant for array
quality assessment and normalization. Data from microarray experiments are obtained
through an elaborated procedure that involves many potential variations. Therefore,
stringent assessment should be performed to ascertain the good quality of the arrays.
Several techniques can be used to assess the quality (Figure 1.1.2). For example, vi-
sual inspection of images created from raw microarray data can easily identify the
problematic arrays with spatial artifacts, as shown in Figure 1.1.2a, b. Examining the
distribution of probe intensities through all arrays can efficiently detect one or more
arrays that are distinct from the others. For example, among six samples shown in
Figure 1.1.2c, d, the distributions of intensities of first three samples are different from
the other three samples. Furthermore, sample 8 and 9 (Figure 1.1.2e) show a bimodal
distribution with a second mode at the tail of the histograms (indicated by arrow),
which depart from the other four samples in the same plot. This observation reflects
the presence of abnormally high intensities in these two samples. Additionally, vari-
ous graphical tools, such as plots for RNA degradation, relative log expression (RLE)
and normalized unscaled standard error (NUSE), can facilitate the determination of
whether an array should be removed from further analysis or handled with caution.
In Figure 1.1.2f, g, two sets of samples without and with RNA degradation are shown,
respectively. In sample 7-12, the intensities decrease towards 3’ end, indicating the
occurrence of RNA degradation and bad quality of the samples.
5
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Figure 1.1.2: Quality assessments of microarray data.
(a) Image plot of the log intensities for a microarray sample with high quality. (b)
Image plot with spatial artifacts indicate a problematic array. (c) Boxplots of un-
processed log scale probe intensities for 6 arrays, i.e., sample 1-6. (d) Histograms of
raw log scale intensities for sample 1-6. (e) Histograms of raw log scale intensities for
sample 7-12. Sample 8 (yellow) and 9 (purple) have a bimodal distribution, reflecting
spatial artifacts as indicated in (b). The second mode at the tail of the histograms is
the result of samples with abnormally high intensities. (f) RNA degradation plots of
sample 1-6. (g) Sample 7-12 with a different 3’/5’ trend may indicate RNA degrada-
tion.
The variability of data might be resulted from non-biological factor. In order to
make reliable comparison of data from multiple arrays, the normalization procedure
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is essential, that controls technical variation across arrays. Many methods have been
proposed. The mean-signal normalization method, also called scaling, was used in
MAS 5.0 developed by Affymetrix. In MAS 5.0, a baseline array is selected and av-
erage expression level of each array is set to have the same value as selected array.
The rationale behind this method is that same tissues and development stages may
have similar mRNA quality. A more frequently used normalization method is quantile
normalization, which makes the distribution of probe intensities the same for each
array (Bolstad et al., 2003).
The goal of exploratory analysis (i.e., the second step of microarray data analysis) is to
understand the relationships between samples and to reveal patterns or structures in
the context of genome-wide data. Microarray data usually contain over 40,000 probes
or probe sets for each sample, which makes visualization of samples rather difficult and
limits immediate exploration of the data (Ringne´r, 2008). Such high-dimensionality
problem can be resolved by using dimension reduction or feature reduction techniques.
Principal component analysis (PCA) is the most widely used algorithm that reduces
the dimensionality of the data while retaining most of the variation in the data set
(Jolliffe, 2005). Since the gene expression is, in most of the cases, highly correlated,
many probes may measure the same coregulated biological process. PCA therefore ac-
complishes data reduction by converting the 40,000 dimensions into a smaller number
of artificial variables, called principal components (PC), which capture most of the
variance within the data. Accordingly, each sample can be represented and visualized
by only a few components. In exploratory analysis, the first, second or third compo-
nents are often the most sufficient ones. Accordingly 2-dimensional or 3-dimensional
plot can be used to assess the similarities and differences between samples. Figure
1.1.3 shows an example of PCA analysis of a microarray data set generated from
pluripotent cells and somatic cells. According to the distribution of the proportion
of variance, the first PC (PC1) captures around 57% of data variance and the second
PC (PC2) nearly 27%. Hence, PC1 and PC2 corresponded to a total of more than
80% of the variance within the data and were used to position microarray samples
7
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on a 2-dimensional space. As a result, the induced pluripotent stem cells (iPS) were
clustered closely with embryonic stem cells (ESC) and were separated from somatic
cells (i.e., mouse embryonic fibroblasts, MEF and neural stem cells, NSC) on the basis
of first two PC (i.e., PC1 and PC2), which is in line with the stem cell property of iPS.
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Figure 1.1.3: Principal component analysis (PCA) of a microarray data set.
(a) The variance of the principal components when PCA is applied to all genes with
expression levels for all samples. The components are sorted by the amount of vari-
ance in the data they represent. (b) A 2-dimensional PCA plot using PC1 and PC2.
In the plot, each dot represents a microarray dataset. ESC (blue), embryonic stem
cells; MEF4F iPS (purple), MEF derived 4 factor induced pluripotent stem cells;
NSC2F iPS (red), NSC derived 2 factor induced pluripotent stem cells; MEF (green),
mouse embryonic fibroblasts; NSC (orange), neural stem cells. The microarray profiles
were retrieved from GSE11274 and GSE10806.
Hierarchical clustering (HC) is another frequently used exploratory method in gene
expression analysis (Eisen et al., 1998). It quantifies the similarity of arrays by cal-
culating the distance between them in a pair-wise manner. The relationships of array
samples are then subjected to a tree-like graph called dendrogram (Figure 1.1.4a).
Analogous to PCA results (Figure 1.1.3), HC reveals two large clusters, representing
pluripotent cells and somatic cells, respectively. Hierarchical clustering algorithm can
be applied using either an agglomerative (bottom-up) or a divisive (top-down) ap-
proach. In the context of microarray analysis, agglomerative clustering begins with
each array as its own cluster and iteratively combines two closest clusters into a new
cluster. The process is repeated until all arrays are in one cluster. Conversely, divisive
clustering starts with all arrays in one cluster and repeatedly divides the most hetero-
8
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geneous cluster into two until all arrays are in their own cluster (Gentleman, 2008).
In order to determine which clusters should be combined, or where a cluster should be
divided, quantification of similarity between arrays is required and achieved by using a
distance metric (e.g., Euclidean distance, Pearson correlation coefficient) and linkage
criterion (e.g., average, single or complete linkage method; Gentleman 2008). The
selection of these parameters would influence the composition of the clusters (Figure
1.1.4b, c).
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Figure 1.1.4: Hierarchical clustering analysis of microarray data sets.
(a) Clustering of microarray data as shown in Figure 1.1.3 with Pearson correlation
coefficient (PCC) and average linkage method. Height of the join indicates the distance
between the left and right branches. (b-c) Comparison of the dendrogram plots of
clustering with PCC and average linkage method (b) and cluttering with Euclidean
distance and single linkage method (c). The microarray profiles were retrieved from
GSE11274 and GSE10806.
PCA and HC are very efficient algorithms and routinely used for analyzing and un-
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derstanding microarray data, such as for the investigation of the class composition
and the identification of outliers or low-quality arrays. However, one caveat to the
application of PCA is that PCA results depend critically on the preprocessing of the
data and selection of variables (Ringne´r, 2008). For example, if there are only a few
genes out of a thousand that differ between two samples, clustering by PCA might not
yield meaningful results due to the lack of differentiation. In comparison to other clus-
tering methods, hierarchical clustering is more sensitive to noise and might not lead
to reproducible results (Garge et al., 2005). Therefore, applying additional clustering
algorithms such as k-means, self-organizing maps, or non-negative matrix factorization
(NMF) might help us to further verify the results and gain more insights about the
structure of the data (Schuldt et al., 2011).
The primary aim of microarray analysis is to identify genes that have been differentially
expressed between sample groups. The fold change analysis is the simplest approach
to detect the differentially expressed genes, which have their expression ratio above or
below an arbitrarily defined ratio (i.e. 2 fold) (Draghici, 2002). However, this method
is insufficient due to the lack of a statistical basis. To overcome this issue, many sta-
tistical tests have been introduced and developed to evaluate hypotheses about gene
expression changes in terms of significance and confidence (Draghici, 2002; Gentleman,
2008). We may propose the null hypothesis that a gene is not differentially expressed
between two groups of samples, and then use a statistical test such as t-test, ANOVA
or a permutation-based test to determine whether we can reject the null hypothesis
with p-value < 0.05.
In general, statistical tests are either parametric or nonparametric. The parametric
tests, such as t-test and ANOVA, assume that the data follow a particular distribu-
tion (e.g., normal distribution), whereas the nonparametric tests, such as the Mann-
Whitney test or permutation tests, make less stringent assumptions on the data dis-
tribution (Lin et al., 2013). The advantage of statistical tests over simple fold change
analysis is that, in addition to the difference of the means between the different groups,
the variance is estimated to assess the significance of the results (Schuldt et al., 2011).
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However, small expression changes can be statistically significant without necessarily
being biologically important. Therefore, the differentially expressed genes should be
defined using a statistical criterion and a fixed fold change ratio.
One important aspect of statistical tests is multiple testing corrections (Benjamini
and Hochberg, 1995). In microarray data analysis, the differential expression test is
repeatedly applied. For example, if we perform 10,000 tests of a null hypothesis that is
actually true, using p-value criterion of 5%, we can expect to reject the null hypothesis
in 500 cases (=10,000 x 5%) just by chance. In other words, according to the statistic
test, 500 genes that are actually not differentially expressed will be determined as
differently expressed genes. Therefore, we need to choose a more stringent p-value
cut-off to avoid such false-positive errors. Many approaches of multiple testing cor-
rections have been proposed to address this problem (Gentleman, 2008). One popular
and appropriate approach in the context of microarray analysis is the false discovery
rate (FDR; Benjamini and Hochberg 1995). The FDR is defined as the expected pro-
portion of false positives in genes that are detected as being differently expressed. A
family-wise error rate (FWER) can be alternatively used to the FDR approach. One
common choice is Bonferroni correction with alpha of 0.05 that leads to smaller lists
of differentially expressed genes (Schuldt et al., 2011). On the other hand, it may
eliminate the biologically true expression changes.
To organize the microarray results in biological context and help us to design bi-
ological hypotheses, numerous bioinformatics methods are available to evaluate the
differentially expressed genes generated from inferential statistics. The identification
of regulatory motifs from DNA sequences is of pivotal importance in the analysis of
gene regulation. A motif is a short sequence pattern that recurs in a group of related
DNA sequences. Such motif is often presumed to have a biological function relating
to protein-DNA binding, mRNA processing, and transcription (D’haeseleer, 2006). In
the context of microarray analysis, we assume that a group of co-regulated genes may
share common motifs in their DNA sequences. Based on this assumption, motifs can be
detected by tools like MEME (http://meme.sdsc.edu/meme/cgi-bin/meme.cgi). The
11
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identified motifs are either de-novo or known motifs that are associated with tran-
scription factors. The known motifs may reveal the interesting regulatory link be-
tween genes and their regulators (i.e., transcription factors). Gene set (or pathway)
enrichment analysis (GSEA; Subramanian et al. 2005) is also a common practice in
microarray analysis. It is able to add more statistical power by “borrowing signifi-
cance” from, for example, many members of a biological pathway or a collection of
function-related gene groups. This basic concept has revolutionized microarray. Tools,
such as GSEA and Database for Annotation, Visualization and Integrated Discovery
(DAVID, Da Wei Huang et al. 2008), provide excellent means to investigate novel
data within the context of existing biological knowledge (Jiang and Gentleman, 2007;
Schuldt et al., 2011).
To obtain a biological validation by alterative approaches or more precise measure-
ments is inevitably important for microarray-based bioinformatics results. A study by
Ioannidis et al. 2008 showed that, even when the microarray data is publicly avail-
able, independent researchers could not reproduce a large fraction of statistic-based
findings. One reason is that, state-of-the-art microarray analysis is a multi-step proce-
dure, which utilizes sophisticated normalization methods and statistical frameworks.
For instance, the number of significantly differentially expressed genes that can be
detected depends on the preprocessing method, filtering, and data transformations
(Hackstadt and Hess, 2009). Choosing different algorithms or tuning parameters may
lead to different results. For this reason, one should make sure that the bioinformatics
pipeline used in a particular study is statistically sound and reproducible. Additionally,
representative genes can be subjected to an independent assay, such as quantitative
RT-PCR for gene expression.
12
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1.2 Epigenomic Profiling by Next Generation Se-
quencing
1.2.1 The Rise of DNA Sequencing Technologies
DNA sequencing is the determination of the precise order of nucleobases (i.e., Adenine,
Thymine, Cytosine, Guanosine) in a DNA sample. The conventional sequencing
approach called Sanger method or dideoxy method was invented in the mid-1970s
(Sanger et al., 1977), which uses a DNA polymerase to produce DNA chains of varying
sizes. The key feature of Sanger biochemistry is the dideoxynucleotide triphosphates
(ddNTPs), which lack the 3′OH group and are able to stop the chain elongation.
Thereby, the Sanger sequencing method is also called the chain termination method.
Over the next three decades of its invention, the Sanger sequence process has been
gradually improved in terms of sequencing speed, accuracy and cost (Hunkapiller et al.,
1991). For instance, the capillary electrophoresis based sequencing approaches derived
from Sanger method in the early 1990s, can handle 96 or 384 samples simultaneously
and achieve reading 750 to 1,000bp with a high accuracy (Shendure and Ji, 2008).
However, such Sanger biochemistry based methods only provide a low level of paral-
lelization, which are inadequate for the entire genome sequencing.
Over the past 10 years, advances in genome sequencing have progressed rapidly (Shen-
dure and Ji, 2008). Several entirely new strategies for DNA sequencing, referring to as
next generation sequencing (NGS), have been designed, such as pyrosequencing devel-
oped by Roche (former 454 Life Scicence), SOLiD sequencing by Life Technologies and
reversible dye terminator techniques by Illumina (Pareek et al., 2011). These novel
NGS methods are highly parallelized that enable rapid sequencing of millions of DNA
molecules in a single sequencing run. Accordingly, the cost of sequencing has been
greatly reduced.
The ENCODE (the Encyclopedia Of DNA Elements) project, launched by the US
13
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Method Description Application 
ChIP-seq Chromatin immunoprecipitation sequencing  
Transcription factor binding sites 
Histone modifications 
DNase-seq  DNase I hypersensitive sites sequencing  
Open chromatin 
Accessible regions in chromatin 
FAIRE-seq  Formaldehyde-assisted isolation of regulatory elements sequencing  
Open chromatin 
Accessible regions in chromatin 
ChIA-PET Chromatin interaction analysis by paired-end tag sequencing  
Three-dimensional arrangement of 
chromatin 
ChIRP-seq  Chromatin isolation by RNA purification sequencing IncRNA-chromatin interaction 
MeDIP-seq  Methylated DNA immunoprecipitation sequencing  DNA methylation 
RRBS  Reduced representation bisulfite sequencing  DNA methylation 
BS-seq/
MethylC-seq 
Bisulphite conversion followed by 
sequencing DNA methylation 
RNA-seq  RNA sequencing 
Expression level of mature transcripts 
and small RNA 
Alternate splice variants  
GRO-seq  Global run-on sequencing  Transcriptionally engaged PolII Determine direction of transcription  
NET-seq  Native elongating transcript sequencing  Nascent transcript bound to RNA PolII  
Table 1.2.1: The various applications of next generation sequencing tech-
nologies.
National Human Genome Research Institute (NHGRI) in 2003, is a prime example
of applying NGS methods. This project successfully identified and characterized the
functional elements in the human genome sequence (Birney et al., 2007; Feingold et al.,
2004). The project also promoted and supported the advance in NGS methods. In
2008, a series of projects funded by NHGRI has initiated and aimed at sequencing
a human genome for $1000 or less. Nowadays, NGS methods are routinely used to
sequence prokaryotic genomes and more complicated eukaryotic genomes. They also
make it possible to conduct personal genome sequencing, which allows to identify novel
single-nucleotide polymorphisms (SNPs) and structural variations, or to assemble new
sequences (Snyder et al., 2010). Furthermore, sequencing technology has evolved be-
yond the analysis of DNA sequences. Coupled with different techniques, NGS has
helped to create new approaches that provide important new insights into the molec-
ular mechanism of genome organisation and cellular function (Soon et al., 2013). For
14
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example, NGS has been extensively used to analyze transcript production, chromatin
structure, transcription factor binding, histone modifications and DNA methylations
(Table 1.2.1).
1.2.2 Core Concept of Next Generation Sequencing
A variety of strategies and platforms for next generation sequencing have been devel-
oped, such as microchip-based electrophoretic sequencing, sequencing by hybridization
and cyclic-array sequencing (Blazej et al., 2006; Margulies et al., 2005; Shendure et al.,
2005; Soni and Meller, 2007). Despite their diversity, the work flows of these NGS
methods are conceptually similar (Figure 1.2.1a). In general, the first step of NGS
experiment is library preparation that can be achieved by shearing genomic DNA into
small fragments. The DNA fragments are then subsequently ligated with common
adaptor sequences and subjected to PCR, resulting in a DNA library of PCR prod-
ucts. After PCR amplification, a PCR colony (i.e., polony) array can be generated
that consists of clonally clustered amplicoms (Figure 1.2.1a). For example, the Solexa
technology from Illumina relies on bridge PCR to amplify clonal sequencing features
(Figure 1.2.1b; Fedurco et al., 2006). The sequencing process is then applied in parallel
to all sequencing features on the polony. For each cycle of sequencing, image of the ar-
ray is recored in order to detect the fluorescent labels incorporated with each extension.
Accordingly, the order of nucleobases of each feature on the polony can be determined.
NGS can be subjected to various applications, depending on the library enrichment.
For example, chromatin immunoprecipitation followed by deep sequencing (ChIP-seq)
has been used extensively to determine DNA binding patterns of transcription factors
or histone modifications (Bardet et al., 2011; Soon et al., 2013; Valouev et al., 2008).
Using a specific histone antibody (e.g., histone H3 (Lys4) tri-methylation antibody),
DNA fragments that contain a particular histone modification pattern can be selected
for sequencing (Figure 1.2.2a). Analogously, using a specific transcription factor anti-
body, TF-binded DNA fragments can be precipitated (Figure 1.2.2a). Genome-wide
DNA methylation can be measured by three NGS methods, including MeDIP-seq,
15
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RRBS and BS-seq (Table 1.2.1). The most prominent difference of these methods
originates from the approaches of translating DNA methylation patterns into DNA se-
quence information. MeDIP-seq retrieves methylated fragments from sonicated DNA
using a specific antibody for 5-methylcytosine, whereas RRBS and BS-seq rely on
a chemical reaction that selectively converts unmethylated (but not methylated) cy-
tosines into uracils (Bock et al., 2010).
1. DNA fragmentation 2. In vitro adaptor ligation 
3. Generation of polony array 4. Cyclic array sequencing 
(>106 reads/array ) 
Cycle 1 Cycle 2 Cycle N 
base 1 base 2 base N 
a 
b 
Figure 1.2.1: The core concept of NGS technologies.
(a) Work flow of NGS. Genomic DNA sequences are fragmented and ligated with
common adaptors, and are subsequently subjected to amplification procedure (i.e.,
generation of a polony array that consists of millions of immobilised PCR colonies,
known as polonies). The cyclic sequencing is then applied to all polonies in parallell.
(b) Amplification of DNA sequencing features using bridge PCR. Briefly, the adaptor-
flanked DNA fragments in the library are used as PCR templates. They first attach
to a solid substrate that is coated with the complimentary adaptor sequences. After
PCR amplification, a single template of DNA fragment can form a clonal cluster, which
contains over 1,000 copies of the template. This procedure is also referred to as the
generation of polony array. Figures were modified and adapted from Shendure and Ji,
2008.
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1.2.3 Translating Next Generation Sequencing Data into Bi-
ology
The massive amount of data produced by NGS technologies is posing challenges for
bioinformatics and data mining. On the other hand, it also promotes the development
of novel bioinformatics tools. Taking ChIP-seq for a transcription factor as an exam-
ple, a single experiment run may generate 5 to 20 GB (gigabytes) raw data depending
on the sequencing depths and antibody affinity of the investigated transcription factor.
The aim of the experiment is to identify the genomic regions that are enriched in a
pool of specifically precipitated DNA fragments, in which protein-DNA binding may
take place. To achieve the goal, a general pipeline needs to be applied on NGS data
(Figure 1.2.2b).
Briefly, the raw sequencing data are subjected to quality control (QC). Poor quality
reads (e.g., reads with base calling errors or insertions/deletions) and primer/adaptor
contamination are common artifacts in the NGS data, which may influent significantly
on downstream analysis (Patel and Jain, 2012). These sequencing artifacts can be min-
imized by QC. The good quality reads are then aligned to reference genome using fast
mapper algorithms, such as Bowtie (Langmead and Salzberg, 2012; Langmead et al.,
2009) or BWA (Li and Durbin, 2009). Some genomic regions may have high density
of mapped reads. These regions are considered to be the transcription factor binding
sites and are also referred to as peaks. The identification of peaks (i.e., peak calling)
can be achieved by using different approaches or algorithms. MACS is one of the most
popular peak callers for transcription factors (Feng et al., 2012; Zhang et al., 2008).
The algorithm takes advantages of the directionality of the reads and models read
distribution by a Poisson distribution to find candidate peaks with a significant read
enrichment. Various downstream statistic and bioinformatic analysis can be applied
after the identification of peaks, such as motif analysis to construct putative tran-
scription factor binding sites, differential test to detect differential binding between
two samples. In addition, integrative approaches that analyze ChIP-seq data together
with gene expression data can be designed. For examples, correlation analysis of TF
17
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binding or histone modification peaks with gene expression may help us to understand
molecular mechanism of gene regulation.
35-100bp short reads 
Non-histone  
ChIP 
Histone  
ChIP 
DNA fragmentation 
Immumoprecipitation 
DNA purification 
DNA library preparation 
Massive parallel sequencing 
Generation of ChIP-seq data  Analysis of ChIP-seq data 
Quality control 
Reads alignment 
a b 
Reference genome 
Peak Calling 
-4 -2 0 2 4
0.
0
0.
2
0.
4
x
hx
Reference genome 
Enriched regions  
Reference genome 
Figure 1.2.2: From wet-lab to dry-lab in a NGS experiment.
(a) DNA fragments precipitated by specific antibody (e.g., histone antibody or tran-
scription factor antibody) are prepared as a DNA library and are subjected for massive
parallel sequencing. This figure was modified and adapted from Park 2009. (b) Raw
ChIP-seq data contains millions of sequences with length of 35-100bp, called short
reads. The reads with good quality scores are subjected to alignment procedure to
determine their genomic location using Bowtie or BWA. Regions of high read density
are inferred to be the transcription factor binding sites. These enriched regions are
also referred to as peaks that can be further identified by a peak calling method, such
as MACS.
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1.3 Understanding of Haematopoiesis
Haematopoiesis, the formation of blood cells from hematopoietic stem cells (HSC), is
a well-studied differentiation system, including more than 50 different cell types. In
the adult bone marrow, long-term hematopoietic stem cells (LT-HSC) are multipotent
and self-renewal. During early haematopoiesis, LT-HSC differentiate into multipotent
progenitor cells (MPP) that are the precursors of different lineage-restricted progeni-
tors. Each of these progenitors, such as common myeloid progenitors (CMP), common
lymphoid progenitors (CLP) and erythroid and megakaryocytic progenitors, can fur-
ther give rise to more mature cells. These multistep developmental trajectories in
hematopoiesis are usually demonstrated by hierarchical tree models. (Figure 1.3.1a).
In the classical tree model of hematopoiesis, the segregation of lymphoid and myeloid
lineages represents the earliest fate decision that gives rise to CLP and CMP. CLP
has the potential to be developed into lymphoid cells (i.e., B cells, T cells and nat-
ural killer (NK) cells), whereas CMP is restricted to the myeloid differentiation via
either the granulocyte/macrophage progenitor (GMP) or megakaryocytic/erythrocyte
progenitor (MEP). However, the notion that CLP do not have myeloid potential has
been challenged by some controversary and compelling data. For example, investiga-
tion of multilineage outcomes in mouse fetal liver has shown that myeloid output is
retained during lymphoid specification (Katsura, 2002). In addition, it also suggested
that progenitors following the pathway of erythroid and megakaryocytic development
maintain myeloid potential (Ye and Graf, 2007). Therefore, the conventional scheme
of hematopoietic development is continuously revised and updated.
Alternatively, new models have been proposed, such as the pairwise relationships model
(Ceredig et al., 2009) that makes no assumptions about underlying branching patterns
(Figure 1.3.1b). This concentric model contains individual layers representing differ-
ent levels during hematopoietic commitment and specification. The direction from
the inner-most layer to outer-most layer implicitly corresponds to the hierarchical re-
lationship from root nodes to leave nodes in the tree model. Moreover, this model
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Basophil or mast cell 
Erythrocyte 
Megakaryocyte 
T cell 
NK cell 
B cell 
Monocyte 
DC 
Neutrophil 
Eosinophil 
a b 
T cell B cell NK cell 
Pro-T Pro-B Pro-NK 
CLP CMP 
MEP GMP 
MDP 
CDP 
LMPP 
MPP 
ST-HSC 
LT-HSC 
Erythrocytes 
Macrophages 
Inflammatory DC cDC pDC 
Pre-DC 
Platelets Monocytes Gran. 
Figure 1.3.1: Models of haematopoiesis.
(a) Hematopoietic development is illustrated by a hierarchical tree model. The root
of the model is the hematopoietic stem cells (HSC). The intermediate nodes of the
tree represent early progenitors (e.g., MPP) and lineage-restricted progenitors (e.g.,
CLP and CMP). The leaf nodes resemble specialized mature cell types. The branches
indicate the developmental pathways. cDC, conventional dendritic cell; CDP, com-
mon dendritic cell progenitor; CLP, common lymphoid progenitor; CMP, common
myeloid progenitor; GMP, granulocyte-monocyte progenitor; HSC, hematopoietic stem
cell; LT-HSC, long term HSC; LMPP, lymphoid-primed multipotent progenitor; MDP,
Macrophage-DC progenitor; MEP, megakaryocyte/erythrocyte progenitor; MPP, mul-
tipotent progenitor; pDC, plasmacytoid DC; Pro-B, B cell progenitor; Pro-NK, natural
killer cell progenitor; Pro-T, T cell progenitor; ST-HSC, short term HSC. Solid arrows
represent proofed pathways and dashed arrows show suggested pathways that need
to be further invesitgated. This figure was adapted from Schmid et al., 2010. (b)
A pairwise relationships model of haematopoiesis. The model focused on describing
the developmental potential of the various progenitor cells that have been known and
those that may remain to be investigated. Individual layers in the concentric model
represent different levels during hematopoietic commitment and specification. The
direction from the inner-most layer to outer-most layer implicitly corresponds to the
hierarchical relationship from root nodes to leave nodes in the tree model. This figure
was adapted from Ceredig et al. 2009.
also described that HSC can commit into a specific cell fate through more than one
type of intermediate progenitors. For instance, dendritic cells (DC) can be derived
from either CLP or CMP, suggesting that DC can originate from both lymphoid and
myeloid compartments (Shortman and Naik, 2006).
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a b 
c 
-6 6 0 
Figure 1.3.2: Transcriptional landscape of haematopoiesis.
(a) A repertoire of gene expression microarray samples (> 600) from nine major
lineages of the human hematopoietic system was collected and classified using non-
negative matrix factorization (NMF) algorithm. Accordingly, for each cell type, a set
of genes was detected and defined as cell type-specific gene signatures. All samples
were then subjected to three-dimensional principal component analysis using identified
gene signatures. In the PCA plot, each dot represents a microarray sample. Various
cell types are coloured differently, i.e., HSCs (red); progenitors (purple); erythrocytes
(light green); Granulocytes (dark green); monocytes (pink); B cells (light blue); T
cells (brown); NK cells (orange) and DC (blue). (b) HSC gene signatures extracted
from NMF algorithm are shown as heat map, indicating uniquely high expression in
all HSC samples (red) and some earlier hematopoietic progenitor cells (purple). The
gene expression level was color-coded using a continuous spectrum from blue (lowest
expression level) to red (highest) via white (intermediate). The samples are color-
coded as in (a). (c) Enrichment analysis of gene ontology (GO) terms shows that
HSC gene signatures are functionally related to hematopoietic development (Q. Lin
and M. Zenke, unpublished).
Hematopoietic development is controlled by specific transcription factors, cytokines
and signalling pathways (Doulatov et al., 2012). As an example, DC development
depends on high expression of transcription factor PU.1, which regulates the expres-
sion of the cytokine receptors FMS-related tyrosine kinase 3 (Flt3) and Flt3 signalling
(Carotta et al., 2010; Merad, 2010). Recent advances in high-throughput technolo-
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gies and computational analysis help us to gain more insights in the organization
of hematopoietic cells and the transcriptional regulation of lineage determination.
On the basis of publicly available microarray data, the transcriptional landscape of
haematopoiesis can be constructed to evaluate the precise relations of hematopoietic
lineages (Figure 1.3.2a). Systematic analysis of gene expression profiles of different lin-
eages can also detect cell-specific gene signatures or transcription factors that define
the cellular identities (Figure 1.3.2bc). Epigenetic regulation (e.g., histone modifica-
tion and DNA methylation) is also playing critical roles in lineage fate decisions of
HSC and its progeny (Cui et al., 2009). Genome-wide histone modifications and tran-
scription factor binding analysis by ChIP-seq are able to identify the specific regulators
that coordinate the commitment and specification of precursor cells. They also provide
an immediate access to decipher transcription programmes that drive hematopoietic
differentiation.
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1.4 Thesis Objectives
The main goal of this thesis is to decipher the molecular mechanism underlying the
hematopoietic stem cell development and differentiation, using transcriptome and
epigenome data. The primary goal for my doctoral studies has been to perform the
comparative analysis and to develop integrative approaches to mine various kinds of
high throughput data.
The first aim of this study has been to investigate the molecular events in the course of
dendritic cell (DC) differentiation from hematopoietic stem cells (HSC) using genome-
wide gene expression profiles. To characterize the lineage-specific transcription pro-
grams and to detect known or novel DC specific genes, a comparative analysis of DNA
microarray data of HSC, DC progenitors and DCs has been performed. Furthermore,
the impact of transforming growth factor beta 1 (TGF-β1) signalling on DC subset
specification has been determined.
Chromatin modification and transcription factor binding are often implicated in the
precise control of gene expression. To understand the regulatory mechanism of DC
fate decision, the changes of chromatin modification during DC development have been
examined on genome-wide scale. In addition, a stage-to-stage epigenetic regulatory
framework has been constructed, which drives DC commitment and specification. The
transcription factors, such as PU.1, are of importance in regulation of hematopoiesis.
Therefore, the regulatory circuit of DC development has been further determined,
which allows us to better understand the relationship between DC developmental reg-
ulators.
The epigenetic landscape provides new perspectives for biomarker selection. Particu-
larly DNA methylation (DNAm) plays a critical role for hematopoietic differentiation
and aging of organisms. Some CpG sites reveal almost linear DNAm changes upon
aging and can therefore be used for age-prediction. A major objective of the analysis
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has been to identify age-related CpG sites that interplay best to predict human age.
In addition, another question has been further addressed, i.e., whether an assay based
on bisulfite pyrosequencing of only a small number of CpG sites might be a less costly,
faster, and user-friendly approach with comparable or even better accuracy to DNAm
profiling approaches.
Acute myeloid leukemia (AML) is a hematopoietic disorder characterized by the loss
of normal hematopoietic differentiation and the predominance of abnormal, immature
myeloid cells. The DNA de novo methyltransferase DNMT3A is often mutated in AML
patients that have a poor prognosis. We hypothesized that epigenetic changes in the
DNAm pattern of DNMT3A can mimic the effect of genetic mutations of DNMT3A
in AML. To this end, the DNAm and transcriptional profiles of the DNMT3A gene
have been thoroughly investigated using the AML data set provided by the Cancer
Genome Atlas Research Network (TCGA).
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Methods
2.1 DNA Microarray Analysis
2.1.1 Gene Expression Profiling
RNA samples were subjected to Affymetrix Mouse Genome 430 v2.0 or Affymetrix
GeneChip Mouse Gene ST Arrays (Affymetrix) for the whole genome gene expression
profiling. The raw data of DNA microarrays were pre-processed using R/Bioconductor
(Gentleman et al., 2004; R Development Core Team, 2008). Gene expression levels
were determined by robust multichip average (RMA) or GC-RMA algorithm (Irizarry
et al., 2003; Wu et al., 2004). Gene expression profiles retrieved from public domain
were analyzed by using corresponding annotation packages and normalized by RMA
algorithm.
2.1.2 Principal Component Analysis
Principal component analysis (PCA) was performed using R/Bioconductor. For clus-
tering of microarray samples and visualization, the first two or three principal com-
ponents (PC) were selected, leading to a 2D or 3D representation of PCA plot, re-
spectively. In a PCA plot, each data point represents a microarray sample. The
relationship between two samples is reflected by the distance between corresponding
dots in the plot. Therefore, the more similar gene expression profiles are, the closer
the data points are. In particular, such 2D or 3D representations are displayed using
scatterplots. The 3D plots were generated by using rgl package in R.
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2.1.3 Clustering and Heat Map Representation
Hierarchical clustering was performed in R/Bioconductor with average or ward linkage
method. The Pearson correlation or Euclidian distance was utilized to measure the
correlation between genes or microarray samples. Gene and sample clusterings were
subjected to heat map format and visualized using gplots package in R. In a heat map,
rows represent genes and columns indicate samples. Each cell corresponds to the ex-
pression level of a gene in a certain microarray sample. The cells are usually coloured
using a continuous color spectrum, for example, from blue (i.e., lowest expression
level) via white to red (i.e., highest level). Therefore, heat maps provide an intuitive
and immediate way for pattern recognition. In addition to hierarchical clustering, a
number of other clustering or classification methods is also applied. For instance, the
Fuzzy c-means algorithm in Mfuzz package was applied to classify genes into groups
(Schwa¨mmle and Jensen, 2010). To generate lineage-specific programs upon DC devel-
opment, all differentially expressed genes were subjected to Fuzzy c-means algorithm
and further aggregated into 6 clusters according to their gene expression patterns.
2.1.4 Differentially Expression Test
Differential expression between two conditions was analyzed using t-test in limma
package (Smyth et al., 2004). In a comparison, a fold change that reflects biological
significance is calculated by the difference of gene expression level between conditions.
In addition, p-value that indicates statistical significance is also calculated. Accord-
ingly, the transcripts with a fold change > 2 and p-values < 0.05 were considered
as being differentially expressed. The raw p-values were adjusted by Benjamini and
Hochberg’s method (Benjamini and Hochberg, 1995).
2.1.5 Gene Set Enrichment Analysis
The biological function enrichment of a set of (∼2000-3000) differentially expressed
genes derived from microarray experiments can be explored using gene set enrichment
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analysis. This set of genes of interest was compared with a list of (>10) genes that are
associated with a certain gene ontology (GO) term or a biological pathway. Then the
hypergeometric test was carried out to estimate the association between the gene set
and the GO term or pathway. The raw hypergeometric probabilities were corrected
by Benjamini and Hochberg’s method. Such gene set enrichment analysis was done
by GOstats package or the toolbox of database for annotation, visualization and inte-
grated discovery (DAVID) (Huang da et al., 2009).
2.2 ChIP-seq Analysis
2.2.1 Generation of Raw Sequencing Data
To investigate the histone modifications (H3K4me3, H3K9me3 and H3K27me3) and
the transcription factor (i.e., PU.1) binding events in DC development, chromatin
immunoprecipitation (ChIP) followed by high-throughput DNA sequencing (ChIP-
seq) experiments for MPP, CDP, cDC and pDC were performed in collaboration with
Heike Chauvistre´, MSc, and Kristin Sere´, PhD, Institute for Biomedical Engineering
- Cell Biology, RWTH Aachen University, Aachen, Germany. The experiments were
conducted on an Illumina GAIIx or HiSeq device in collaboration with Dr. Benoˆıt
Hennuy, GIGA, Lie`ge, Belgium and Dr. Vladimir Benes, EMBL, Heidelberg, Ger-
many.
2.2.2 Processing of Raw Sequencing Data
The raw sequencing data usually consists of millions of short reads with the length
of 36∼75 nucleotides. To examining the sequencing errors and trimming low qual-
ity reads, the quality assessment of the raw data was performed by using FastQC
(www.bioinformatics.babraham.ac.uk/projects/fastqc/). The key quality statistics in-
cluding per base sequence quality and sequence duplication levels were calculated. The
short sequence reads that pass the QC tests were aligned to the reference mus muscu-
lus genome (version mm9) using Bowtie (version 0.12.8) with the following parameter
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settings: -m 1 -a - - best - - strata (Langmead et al., 2009). The parameter -m was
specified to 1 to exclude all reads that were mapped to more than one location in the
mouse genome.
2.2.3 Peak Calling and Lineage-specific Peaks
The aligned ChIP-seq data sets of transcription factor PU.1 were processed to iden-
tify genomic regions with sequence enrichment, described as peaks, with the MACS
software (version 1.4.2) using the following settings: -p 1e-3 -m 3,40 -g mm (Zhang
et al., 2008). The histone modification peaks generally cover larger regions than the
transcription factor peaks. We therefore used SICER, a spatial clustering approach
for the identification of ChIP-enriched regions, to identify histone modification peaks
(Zang et al., 2009). Lineage-specific histone peaks were defined as peaks in one lineage
that does not overlap with any other peaks in all three other lineages.
2.2.4 Detection of Differential Peaks
The peaks of all investigated cell types were merged to generate a complete set of
peaks. The coverage of reads within the peaks in the complete set was used to esti-
mate the peak signal. The differential peaks between a pair of cell types were detected
using exact empirical test from EdgeR (Robinson et al., 2010). Peaks with low read
support (i.e., log2-counts-per-million < 3.0) were excluded from further analysis. A
peak was considered differential if it produced a significant fold change and p-value
< 0.01 after Benjamini-Hochberg multiple test correction (Benjamini and Hochberg,
1995).
2.2.5 Identification of PU.1 Co-binding Transcription Factors
We designed an integrative approach to detect the transcription factor (TF) motifs
that are highly enriched in the PU.1 peaks. The corresponding workflow is shown in
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Figure 2.2.1. Firstly, differentially expressed genes upon DC commitment (MPP vs.
CDP) and specification (cDC vs. pDC) were detected as described in 2.1.4. Secondly,
transcription factor motifs were collected from Jaspar (Portales-Casamar et al., 2010),
Uniprobe (Robasky and Bulyk, 2011) and Homer (Heinz et al., 2010). The motifs of
TFs with low gene expressions or low variations upon DC development were excluded
from further analysis. In other words, only motifs of differentially expressed transcrip-
tion factors were taken into consideration. Binding site detection was then performed
within PU.1 differential peaks of differentially expressed genes in a particular cell type.
The motif search was based on Biopython (Cock et al., 2009), utilizing the distribution
of the information content of each motif to define a bit score threshold on the basis
of a false discovery rate (FDR) test. We used the FDR value of 0.1 for all binding
sites. Next, random binding sites were obtained by iteratively performing binding
site detection within randomly sampled sequences. Finally, we employed a one-tailed
Fisher’s exact test to measure if the proportion of differential PU.1 peaks close to dif-
ferentially expressed genes with at least one transcription factor binding site is higher
than the proportion of PU.1 peaks in the random regions. The test was repeated for
all motifs and cell specific differential peaks. Final p-values were corrected using the
Benjamini-Hochberg method (Benjamini and Hochberg, 1995). The corrected p-values
(or enrichment scores) were visualized in heat map format, where dark red indicated
the TFs with potentially co-binding with PU.1 under a particular cell type (Figure
2.2.1).
2.2.6 Construction of DC Regulatory Networks
PU.1 co-binding transcription factors identified in 2.2.5 and selected key DC develop-
ment regulators from literature (e.g., Id2 and Gfi1) were used to build lineage-specific
transcription factor networks. In each network, nodes represent transcription factors
that are connected by edges if there exists co-binding between them. The significance
of such co-bindings in a cell type is indicated by black edges. Furthermore, the direc-
tionality of an edge (from node a to node b) indicates that the binding site of node a
is found in the differential PU.1 peak region close to node b. In addition, nodes are
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colored differently, i.e., enriched transcription factors in red; unenriched transcription
factors in gray; elected key regulators in white. Networks were generated by Cytoscape
(Shannon et al., 2003).
Figure 2.2.1: The workflow of regulatory network inference method.
(a) Detection of differentially expressed genes (DE) between two cell types (i.e., MPP
and CDP). (b) Collection of transcription factor motifs from Jaspar (Portales-Casamar
et al., 2010), Uniprobe (Robasky and Bulyk, 2011) and Homer (Heinz et al., 2010).
(c) Identification of differential peaks (i.e., PU.1 peaks) of the differentially expressed
genes in (a). (d) Motif search within identified peak regions of (c). (e) Enrichment
analysis of transcription factor motifs within identified peak regions of (c). (f) Con-
struction of cell type specific transcription factor regulatory networks (in collaboration
with Dr. Ivan Gesteira Costa Filho, IZKF Research Group Computational Biology,
RWTH Aachen University, Aachen, Germany).
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2.3 DNA Methylation Analysis
2.3.1 DNA Methylation Profiling
DNA methylation (DNAm) profiles generated in-house or retrieved from public domain
were analyzed using the Human Methylation 27 BeadChip or Human Methylation 450
BeadChip (Illumina, San Diego, USA). DNAm levels, described as beta values, are
recorded for each locus in each sample. In other words, DNAm levels is evaluated at
CpG level. The resulting beta values represent the presence or absence of DNAm. A
value of close to 1 indicates that the corresponding CpG site is highly methylated.
Quantile normalization of the raw data was performed to minimize the chip effect.
2.3.2 Data Collection and Selection of Age Related CpGs
In order to obtain a large sample collection, all available DNAm profiles of normal
blood samples that were generated from the HuamnMethylation27 BeadChip plat-
form were assembled. In total, 575 blood samples originated from individuals of age
from 0 to 78 were collected. Accordingly, the data set can be represented as a com-
plete matrix where rows represent 27,578 CpG sites and columns indicate 575 samples.
Each cell reports the beta value of a particular CpG site in a sample. For each CpG
site, an array of 575 beta values was extracted and the correlation between these beta
values and corresponding age was evaluated by Pearson correlation coefficient (R).
From all CpG sites, a subset of 102 sites that yielded R > 0.85 or R < -0.85 were pri-
oritized, indicating a high degree of correlation between the methylation level and age.
Therefore, these CpG sites were considered as age related CpG sites (AR-CpGs) and
further utilized as features to generate a multivariable linear model. The entire set of
samples was divided into a training set and a test set. Leave one out cross-validation
was applied to evaluate the performance of the model. In other words, 574 samples
were used to train the model and the remaining one was used to test the quality of the
model. Such cross-validation was performed 575 times, i.e., each sample was used once
as test sample. The model with the best performance was selected and further applied
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to another data set GSE40279 that was generated from the HumanMethylation450
BeadChip platform and consisted of 656 samples with individuals of age 19-101 (Han-
num et al., 2013). Therefore, this data set was used for external validation of the
linear model.
2.3.3 Sequence and Enrichment Analysis of AR-CpGs
Nucleotide sequence of 2kb centered by each AR-CpG was retrieved from human
genome NCBI36/hg18. Accordingly, 102 nucleotide sequences associated with 102
AR-CpGs were collected. FIMO (Find Individual Motif Occurrences) from MEME
Suite was utilized to scan for known transcription factor binding motifs within each
nucleotide sequence (Bailey et al., 2009; Grant et al., 2011). The search for these
binding motifs was repeated on the basis of all 27,578 CpG sites. Therefore, for each
binding motif, the frequency of occurrence among 102 AR-CpGs and all CpG sites
was recorded and utilized to calculate a p-value using Fisher’s Exact Test. It should
be noted that 44 positively correlated and 58 negatively correlated AR-CpGs were
separately considered for the further enrichment analysis. Thus, the significance was
compared between all CpG sites and 44 or 58 AR-CpGs, respectively. From all known
transcription factor binding motifs, the five most significantly enriched motifs within
positively or negatively correlated AR-CpGs were identified, respectively, for the as-
sessment of biological functions of AR-CpGs. The sequence logo plots were generated
by seqLogo package in R for these most enriched motifs (Bembom, 2007). In addition,
the frequency of nucleotides in the flanking regions was determined for 10 up- and
down-stream positions around each AR-CpG. Therefore, for positively and negatively
correlated AR-CpGs, the enrichment of nucleotides at each position was monitored.
The corresponding sequence logo plots were also generated.
Moreover, histone modifications at AR-CpG loci were analysed in ChIP data for ESCs
(GSE8463; GSE29611), CD14+ monocytes (GSE29611), and MNCs (GSE31755). En-
richment of H3K4me3, H3K27me3, the bivalency (modified by both H3K4me3 and
H3K27me3) or neither of them was estimated for positively and negatively correlated
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AR-CpGs in relation to all CpG sites (Fisher’s Exact Test), respectively. Analogously,
the enrichment of Gene Ontology Classification of genes with these two subsets of AR-
CpGs was evaluated in relation to all CpGs on the BeadChip (Fisher’s Exact Test)
and performed with GoMiner software (http://discover.nci.nih.gov/gominer/).
2.3.4 Selection of Epigenetic-Aging-Signature
A computational approach was designed to select epigenetic-aging-signature for age
prediction. First, to obtain a subset of N AR-CpGs for age-predictions based on locus-
specific DNAm levels, the AR-CpGs with above median variations in beta-values (i.e.,
above median level of interquartile range, IQR) were prioritized. The set of 575 samples
was then randomly divided into training and validation sets by defined split-ratios, i.e.,
50/50; 60/40; 70/30; 80/20 and 90/10. For example, ‘60/40’ indicates that 60% of the
samples is used as training set and the remaining 40% as validation set. Next, recursive
feature elimination (RFE) was carried out and implemented in R caret package (Kuhn,
2008). For each run of sample split, a linear model was first trained using the subset
of N selected AR-CpGs, i.e., a global model. The performance of this global linear
model was evaluated on the basis of the validation set. In addition, the same training
set was applied to select 5 AR-CpGs that produced the best result while training. The
corresponding linear model generated from these 5 AR-CpGs was considered a local
model. The performance of the local model was compared with the global model. If
the local model outperformed, the 5 AR-CpGs were recorded. Otherwise, this run was
failed for feature selection. For each split ratio, 100 different runs were performed.
From all successful selection runs, the frequency of individual selected AR-CpGs was
counted. The five most frequent AR-CpGs were further considered for locus specific
DNAm analysis by pyrosequencing. The sequences surrounding cg02228185 (ASPA),
cg25809905 (ITGA2B), and cg17861230 (PDE4C) were best suited for this approach.
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2.3.5 Pyrosequencing and Age-predictions
Initially, pyrosequencing was performed for 82 blood samples (27 from the Depart-
ment of Obstetrics and Gynecology of the University Hospital Aachen; GYN and 55
from Heinz-Nixdorf Recall-Study; HNR) at Varionostic GmbH (Ulm, Germany) to
generate the multivariate model (in collaboration with Carola Weidner and Wolf-
gang Wagner, Helmholtz Institute for Biomedical Engineering, Stem Cell Biology
and Cellular Engineering, RWTH Aachen University Medical School, Aachen, Ger-
many). The model was subsequently validated in 69 samples (19 from the Department
of Oncology, Hematology and Stem Cell Transplantation of the University Hospital
Aachen; HEM and 50 from HNR). The formula of age prediction model is as follow:
Predicted age (in years) = 38.0−26.4α−23.7β+164.7γ. Beta-values at the following
three CpGs were used for age-prediction: (α) = cg02228185; (β) = cg25809905, and
(γ) = a CpG site up-stream of cg17861230 which revealed better correlation with age.
2.3.6 DNAm profiles of DNMT3A
DNAm profiles of AML samples generated from the HumanMethylation450 BeadChip
platform were downloaded from TCGA (https://tcga-data.nci.nih.gov/tcga/). The
450k BeadChip comprises > 480,000 CpGs of which 79 CpGs related to the gene
DNMT3A. However, we only focused on 72 CpGs with beta-values in all TCGA sam-
ples (missing values might be due to low bead numbers). These 72 CpGs were also
considered for graphical representation. In addition, for each of > 480,000 CpGs, the
differentially methylation analysis was carried out. Raw p-values were calculated us-
ing limma t-test in R/Bioconductor and further adjusted by the Benjamini-Hochberg
method (Benjamini and Hochberg, 1995). CpG sites with adjusted p-value < 0.05 and
an additional cut-off of 20% DNAm difference were considered as being differentially
methylated.
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Results
3.1 Transcriptome Kinetics in Dendritic Cell De-
velopment
3.1.1 Dendritic Cell Development
Dendritic cells (DC) are a sparsely but widely distributed population of hematopoietic
cells that are essential for antigen presentation and T cell priming. The unique role
of DC in bridging the innate and adaptive immune responses relies on their extraordi-
nary capacity to capture, process and present antigens to T cells (Shortman and Liu,
2002). DC have been divided into distinct subsets depending on their phenotypic,
genetic and functional diversity. The conventional DC (cDC) and the plasmacytoid
DC (pDC) represent two most important subset of DC (Liu et al., 2009; Shortman
and Naik, 2006). cDC, known as classical DC are predominant DC subset and are
specialized for antigen processing and presentation. cDC form a small subset of tissue
hematopoietic cells that populate most lymphoid and nonlymphoid tissues (Merad
et al., 2013). pDC represent a small subset of DC that has a distinct life cycle than
cDC. pDC are quiescent cells that mainly accumulate in the blood and lymphoid
tissues. Unlike cDC, pDC have poor antigen presenting capacity, due to the low ex-
pression of MHC-II and integrin CD11c (Reizis et al., 2011). However pDC are able
to produce large amount of type I interferons (INFs) during viral infection (Belz and
Nutt, 2012; Perussia et al., 1984).
DC development shows remarkable plasticity, and DC have been shown to develop
from both lymphoid and myeloid compartments via Flt3-expressing progenitors (Felker
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et al., 2010; Karsunky et al., 2003; Waskow et al., 2008). Recent studies (Fogg et al.,
2006; Naik et al., 2007; Onai et al., 2007) identified clonogentic DC progenitors (i.e.
macrophage/DC progenitor, MDP and common DC progenitor, CDP). It was also sug-
gested that MDP generates macrophages and DC, whereas CDP are direct DC progen-
itor and do not give rise to other cell types. However, the molecular mechanism under-
lying the development and differentiation of DC from hematopoietic stem/progenitor
cells remains poorly understood.
In this study, we generated and analyzed a set of DNA microarray data including
MPP, CDP, cDC and pDC. Based on the analysis, the DC progenitor and lineage-
specific gene signatures were identified. We also observed that CDP as the direct DC
progenitor, acquire DC-primed gene expression patterns upon DC development. Sub-
sequently, we evaluated the effect of TGF-β1 signaling by DNA microarray. We found
that TGF-β1 promotes DC development and directs CDP differentiation towards to
cDC.
3.1.2 Global Gene Expression Profiles of Hematopoietic Stem
Cells and DC Subsets
We established an in vitro culture system that mimics DC development from multi-
potent progenitors (MPP) to common DC progenitors (CDP) that are further differ-
entiated into conventional DCs (cDC) and plasmacytoid DCs (pDC) subsets (Figure
3.1.1a; Felker et al. 2010). This system resembles two critical steps in the DC differen-
tiation pathway, including first DC commitment from hematopoietic progenitor cells
to the direct DC precursors, and second, DC specification from the DC precursors
to distinct subtypes of DCs. To explore the transcriptional dynamics involved in DC
commitment and specification, RNA samples from MPP, CDP, cDC and pDC were
isolated and subjected to DNA microarray analysis (Affymetrix).
Genome-wide gene expression profiles of four investigated cell populations (i.e., MPP,
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Figure 3.1.1: Global transcriptome dynamics in DC development.
(a) Schematic representation of in vitro culture system for DC development, including
DC commitment from MPP to CDP and DC subset specification from CDP to ei-
ther cDC or pDC. (b-c) Principal component analysis (PCA) of microarray data sets
from in vivo CDP and in vitro generated MPP, CDP, cDC, and pDC. The position
of a microarray data set was determined by the combination of PC1 and PC2 (b)
or PC1 and PC3 (c). In addition, each data set was represented by symbol: blue
triangles, MPP; orange squares, in vitro CDP; green diamonds, in vivo CDP; red
dots, cDC; purple triangles, pDC. The first three principal components PC1, PC2 and
PC3 showed variances of 46.3%, 22.2% and 15.9%, respectively. Furthermore, hori-
zontal (uni-directional) arrow indicates the DC differentiation pathway. The vertical
(bi-directional) arrow highlights the difference between in vivo and in vitro cultured
cells.
CDP, cDC and pDC) were analyzed by principal component analysis (PCA) to il-
lustrate the relationships among different samples. The first principal component
demonstrates the developmental trajectory that starts with the hematopoietic stem
cells (i.e., MPP) and ends with terminal differentiated cells (i.e., cDC and pDC) (Fig-
ure 3.1.1b). The direct DC progenitors (i.e., CDP) are positioned downstream of MPP
suggesting their lineage commitment toward DC pathway. To investigate similarity of
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the in vivo and in vitro generated CDPs, in vivo CDP were also taken into consider-
ation (Figure 3.1.1b, c). PC2 captured the expected differences between in vivo and
in vitro cultured cells, that was indicated by different vertical positions along PC2.
However, PC1 and PC3 surprisingly clustered in vivo CDP with in vitro amplified
CDP, indicating a high degree of similarity in their global gene expression profiles.
In addition, PC3 also separated two DC subsets from each other, reflecting that they
acquired distinct transcription programs upon DC differentiation. Taken together,
our DNA microarray profiles of hematopoietic stem cells and DCs from in vitro DC
culture system provide a comprehensive transcriptomic map and reliable resource to
study the molecular mechanism of DC development.
3.1.3 CDP Acquire Expression Patterns Primed for DC De-
velopment
DC commitment occurs at the CDP stage (Naik et al., 2007; Onai et al., 2006). To
gain insight into the molecular dynamics during the DC commitment, we focused on
comparative analysis of the DNA microarray profiles of MPP and CDP. A total of
429 genes were found to be differentially expressed (DE) (p-value < 0.05, t-test) by
more than 2-fold between MPP and CDP. These DE genes were further subjected to
hierarchical clustering analysis and classified into seven distinct clusters. Figure 3.1.2a
shows a DC-like expression profile in CDP, including genes that are lowly expressed
in MPP, moderately upregulated in CDP and further highly expressed in cDC and/or
pDC (cluster I, II and IV in Figure 3.1.2a). In contrast, the MPP-specific genes in
cluster VI were already down-regulated in CDP and expressed at comparably low level
in DCs. Interestingly, CDP are clustered with DC using these DE genes, suggesting
high similarity between CDP and DC.
An in-depth examination of several gene clusters allows us to identify known and novel
lineage specific genes. The key transcription factors and membrane proteins identified
from each cluster were listed in Figure 3.1.2b. Cluster I consists of Pan-DC genes
that are specifically expressed in both cDC and pDC (Figure 3.1.2a, b), such as Flt3
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(Onai et al., 2006). Many of them have been proven to be of importance in DC de-
velopment, including transcription factors Irf5, Irf8 and chemokine receptors Il10ra
and Ccr5. Cathepsin and caspase genes (i.e., Ctsh, Ctss, and Caps6) identified from
cluster I were also functionally associated with DCs (Nakagawa et al., 1999).
Cluster Gene Function Gene 
I Pan-DC Membrane Protein Flt3, Il10ra, Ccr5 
Transcription Factor Irf5, Irf8 
Other Ctsh, Ctss, Casp6 
II pDC Membrane Protein Tlr7, Cd28, Cd38 
Transcription Factor Tcf4, Notch1 
III MPP&DC Membrane Protein Igflr 
IV cDC Membrane Protein Cx3cr1, Tlr2, Fcgr1 
Transcription Factor Id2 
Other Lgmn, Ctsc 
V CDP Membrane Protein Csflr 
Transcription Factor Id3 
VI MPP Membrane Protein Ncam1, Trfr2, Prom1, Itga6, Cd34 
Transcription Factor Gata2, Cebpa, Nfe2, Tal1, Gfi1 
VII MPP&cDC Membrane Protein Kit 
b a 
Cluster M
P
P
1 
M
P
P
2 
C
D
P
1 
C
D
P
2 
cD
C
1 
cD
C
2 
pD
C
1 
pD
C
2 
-2 2 0 
I 
II 
III 
IV 
V 
VI 
VII 
Figure 3.1.2: CDP exhibit a DC-primed gene expression pattern.
(a) Hierarchical cluster analysis of gene expression in MPP, CDP, cDC and pDC. Gene
expression data of 429 genes that were significantly differentially regulated between
MPPs and CDPs are represented in heat map format. Each row represents a gene
and each column a cell type. Each cell corresponds to the expression level of a gene
in certain cell type and is color-coded using a continuous spectrum from blue (lowest
expression level) to red (highest) via white (intermediate). Representative clusters,
including cluster I: Pan-DC genes; cluster II: pDC genes; cluster IV: cDC genes; and
cluster VI: MPP genes, are highlighted using boxes. (b) Shown is the list of seven
gene clusters. For each cluster, the cluster name and the list of genes associated with
a function of interest is provided. For examples, three genes Flt3, Il10ra an Ccr5
identified from cluster I encode membrane proteins.
In addition, cluster II and cluster IV comprised pDC-affiliated and cDC-associated
genes, respectively (Figure 3.1.2a, b). The pDC hallmarks Tcf4/E2-2 and Tlr7 were
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correctly categorized in cluster II (Nagasawa et al., 2008), whereas cDC-specific genes,
such as Id2, Tlr2 and chemokine receptor Cx3cr1 were present in cluster IV (Hacker
et al., 2003). Furthermore, pDC cluster also included many lymphoid-related genes,
for instance, surface makers Cd28 and Cd38. On the contrary, cDC cluster comprised
myeloid genes and genes encoding proteins that involved in antigen presentation (i.e.,
Lgmn and Ctsc).
Cluster VI contained hematopoietic stem/progenitor cell genes that were highly ex-
pressed in MPP. These genes were further down-regulated in CDP and DCs, indicat-
ing the loss of multilineage potential in CDP stage. For example, several transcrip-
tion factors related to cell proliferation and self-renewal (i.e., Gata2, Cebpa, Nfe2,
Tal1 and Gfi1) were lowly expressed or absent in CDP. Additionally, a number of
stem/progenitor cell-related surface proteins, including Ncam1, Trfr2, Prom1, Itga6
and Cd34, were found in this cluster (Ivanova et al., 2002; Ramalho-Santos et al., 2002).
In summary, the set of 429 differentially regulated genes showing great dynamics upon
DC commitment from MPP to CDP were captured in our analysis. The expression of
stem cell related genes was rapidly down-regulated in the CDP stage, indicating the
restriction of transcription program towards to DC lineage. More importantly, genes
critical in DC development were upregulated from MPP to CDP and their expressions
were further enhanced in DCs, suggesting that CDP acquires a DC-primed gene ex-
pression profile.
3.1.4 Lineage-specific Transcriptional Programs upon DC De-
velopment
To further explore the transcriptional dynamics involved in both DC commitment and
specification, we determined changes in gene expression levels between MPP, CDP,
cDC and pDC (i.e., MPP vs. CDP; CDP vs. cDC/pDC and cDC vs. pDC) using
DNA microarray data (Figure 3.1.3a). There are 429 genes that were differentially
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expressed between MPP and CDP; 1773 genes between CDP and cDC; 2181 genes
between CDP and pDC and 1111 genes between cDC and pDC. Therefore, more genes
were differentially regulated during the process of DC subset specification than during
DC commitment (Figure 3.1.3a).
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Figure 3.1.3: Lineage-specific transcriptional programs in DC development.
(a) Four comparative analyses of a pair of cell states were performed. The number of
differentially expressed genes between each pair of cell states is given in red. (b) Differ-
entially expressed genes were clustered according to their expressions in MPP&CDP,
MPP, CDP, DCs, cDC and pDC as indicated. MPP, CDP, cDC and pDC are in 2
replicates. (c) Gene expression data of MPP, MDP, CDP, cDC and pDC obtained
by FACS sorting from mice were clustered using same genes as in (b). MPP, MDP
and CDP, 2, 3 and 3 replicates, respectively; cDC, a panel of CD8+, CD8−CD4+,
CD8−CD4−CD11b+ subsets in 5-6 replicates; pDC in 6 replicates (Miller et al. 2012,
GSE15907). Red, high expression; blue, low expression. MDP, macrophage-DC pre-
cursor; FACS, fluorescence-activated cell sorting.
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In total, 3194 unique genes were identified that were differentially expressed between
one or more pairs of cell states with fold change > 2 and p-value < 0.05. Among them,
210 genes encoded transcription factors (TFs) that included many critical hematopoi-
etic regulators, such as Irf4, Irf8, Batf3, Relb, Id2, Spib and Tcf4 (E2-2) (Merad
et al., 2013). All differentially expressed genes were categorized by their gene expres-
sion patterns in six cell type-specific clusters: progenitors (MPP/CDP), MPP, CDP,
DC (cDC/pDC), cDC and pDC cluster (Figure 3.1.3b, see Methods 2.1.3 for details).
These clusters highly matched to the gene expression profiles of DC progenitors and
DC subsets generated from in-vivo sorted cell populations (spleen and bone marrow,
Figure 3.1.3c).
In progenitor clusters, genes were ubiquitously high expressed in MPPs and CDPs
(Figure 3.1.3b). These genes included metabolism and cell cycle control genes that
maintained the property of DC precursors during commitment. Yet, most of them
were repressed upon DC specification, which related to the growth inhibition and cell
differentiation. For example, Taf4b, known to be involved in the transcription initia-
tion and mediate B cell specific transcription, was down-regulated from DC precursors
to DCs (Wu et al., 2005). The genes in MPP cluster, such as Gfi1, Cebpa, Gata2
and Tal1, were down-regulated from MPP to CDP and had low or no expression in
DCs, reflecting the gradual restriction of development from early hematopoietic pro-
genitors towards DC committed progenitors and DCs (Figure 3.1.3b). The pan-DC
(DCs) cluster comprised the genes that played important roles in cDCs and pDC. For
instance, Flt3 was essential for steady-state DC development. The cDC and pDC clus-
ters identified DC subset-specific genes, which facilitated the DC lineage diversification
(Figure 3.1.3b). In addition, Id2, Zbtb46, Ciita, Irf4, Jun, Bcl6 and Bhlhe40 showing
particular high expression in cDC obviously contributed to establishing cDC identity,
whereas Tcf4/E2-2, a hallmark of pDC was found in the pDC cluster. Taken together,
this analysis captured known regulators of DC development and may help to identify
potential novel DC genes. It also revealed the underlying transcription program for
DC lineage commitment and specification.
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3.1.5 Functional Significance of CpG Islands in DC Develop-
ment
Of all mouse gene promoters, over 60% contain CpG-rich regions, referred to as CpG
islands (CGI). They often serve as cis-regulatory elements to control transcription
of associated promoters. Recent data show that CpG-rich and CpG-poor promoters
differ in DNA methylation and chromatin states, therefore control genes that are ex-
pressed in distinctive manners (Mikkelsen et al., 2007). To determine the functional
significance of CGI in DC development, we categorized genes into non-CGI and CGI
promoter genes (i.e., 36% and 64% of all genes, respectively), based on the existence
of CGI in the promoter region (transcription start site (TSS) +/- 1kb). The pro-
portion of non-CGI and CGI promoters in four sets of differentially expressed genes
(MPP vs. CDP, CDP vs. pDC, CDP vs. cDC and pDC vs. cDC) were calculated, re-
spectively (Figure 3.1.4a). The Fisher’s exact test was unitized to evaluate enrichment.
During the commitment from MPP and CDP, both up and down-regulated genes
showed significant enrichment of non-CGI promoters (49% of up-regulated and 54%
of down-regulated genes in CDP), indicating that CpG-poor promoters were generally
associated with lineage commitment or tissue specific genes. Along with the loss of
plasticity and differentiation from CDP to DCs, down-regulated genes were extremely
enriched by CGI promoters (76% in pDC, 77% in cDC), suggesting CpG-high promot-
ers may play roles in the lineage specification by permanently turning off the early
development related genes. It also implies the CGI promoters may functionally asso-
ciate with the cell plasticity. Furthermore, unlike cDC, pDC represent the terminal
point of their lineage. Accordingly, our data showed that pDC affiliated genes were
largely enriched by CGI promoters (68%). We next analyzed the microarray data gen-
erated from in vivo DC progenitors and DCs in public domain (Figure 3.1.4b). The
results were in consistence with our findings. Taken together, we conclude that the
existence/absence of CpG islands in the promoters was functionally associated with
DC development. The non-CGI promoters were of importance in DC commitment,
while CGI promoters were more involved in DC lineage specification to control the cell
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plasticity and regulatory program of the terminal differentiated cells.
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Figure 3.1.4: Functional significance of CpG islands (CGI) or non-CGI pro-
moters in DC development.
The differential expression analysis was performed using DNA microarray data of in-
house (a; in vitro) and published experiments (b; in vivo; GSE15907). The distribu-
tion of CGI and non-CGI promoters was then calculated for the up and down-regulated
genes of each pairwise comparison. The fraction of CGI (dark yellow) and non-CGI
promoters (light yellow) is shown in a color-coded pie chart. Fisher’s exact test was
applied to estimate the enrichment of each fraction, using the overall distribution of
CGI and non-CGI promoters in respective microarray platform as a universal back-
ground. The number of genes in each fraction is shown. The enriched fraction was
labeled by star (p-value < 0.05 by Fisher’s exact test).
3.1.6 TGF-β1 Signaling in DC development
Transforming growth factor beta1 (TGF-β1) belongs to a well-defined cytokine family
and is involved in a variety of cellular events, such as cell proliferation, differentia-
tion and diverse immune responses (Letterio and Roberts, 1998; Worthington et al.,
2012). Conventionally, TGF-β1 protein exerts its function via activating the Smad-
dependent signaling pathway. TGF-β1 binds to its receptor TGFβRII, forming the
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active TGFβ-TGFβR complex that results in the recruitment and phosphorylation
cascade of TGFβR1 and SMAD2/3. Phosphorylated SMAD2/3 then dissociates from
the receptor complex and binds to SMAD4 in order to translocate to the nucleus
where it acts as a transcription factor to regulate gene transcription (Shi and Mas-
sague´, 2003).
Recent studies revealed that TGF-β1 plays a crucial role in regulating DC develop-
ment (Hacker et al., 2003; Heinz et al., 2006; Ju et al., 2007). TGF-β1-/- mice lack
Langerhans cells (LC), a unique subset of DCs found in the epidermis of the skin
(Borkowski et al., 1996). Subsequent work has demonstrated the similar phenotype in
mice that lack the transcription factor Id2 that is induced by TGF-β1 (Hacker et al.,
2003). However, the influence of TGF-β1 on hematopoietic cells is lineage and context
dependent (Fortunel et al., 2000). TGF-β1 seems to stimulate myeloid-biased cells and
inhibits lymphoid-biased cells (Challen et al., 2010; Kee et al., 2001). Yet, the impact
of TGF–β1 signaling on DC lineage diversification has not been analyzed. Here we
investigated whether TGF-β1 affects the DC subset specification from DC progenitors.
3.1.7 TGF-β1 Promotes DC Development and Impels DC
Subset Specification
To decipher molecular events in response of TGF-β1 in CDPs and its consequences,
we utilized our in vitro culture system to obtain enough cells, and conducted a time
series of TGF-β1 treatment on CDP (Felker et al. 2010; in collaboration with Piritta
Felker, Institute for Biomedical Engineering - Cell Biology, RWTH Aachen University,
Aachen, Germany). Untreated CDP as a control and CDP treated with TGF-β1 for
4, 8, 12 and 24h were subjected to genome-wide gene expression analysis. Upon the
treatment, 3758 genes were significantly regulated (t-test p value < 0.05 and more
than 2-fold by TGF-β1), including known TGF-β1 target genes (i.e., Smad7, Id2 and
Irf4). Hierarchical clustering analysis on samples demonstrates significant differences
in transcriptome profiles from untreated and early treated CDP to 24h TGF-β1 treated
CDP (Figure 3.1.5a). In line with this observation, PCA positioned TGF-β1 treated
45
3. Results
CDPs between untreated CDPs and DC subsets (i.e., cDCs and pDCs), indicating
that TGF-β1 accelerates DC differentiation (Figure 3.1.5b).
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Figure 3.1.5: TGF-β1 promotes DC development.
(a) Hierarchical clustering of TGF-β1-treated (4h, 8h, 12h, 24h) and untreated (0h)
CDP and of cDC and pDC based on 3758 TGF-β1 regulated genes. (b) PCA of TGF-
β1-treated (24h) and untreated (0h) CDP and of cDC and pDC based on 3758 TGF-
β1 regulated genes. The two principal components PC1 and PC3 showed variances of
45.1% and 18.4%, respectively.
Furthermore, clustering analysis was also performed on 3758 TGF-β1 regulated genes
to reveal distinctive gene expression kinetics that coordinate with TGF-β1 treatment
(Figure 3.1.6). In total, six clusters were generated, each of which consisted of 412
to 751 genes. Genes in cluster 5 and cluster 6 showed fast responses to TGF-β1,
whereas genes in cluster 3 and cluster 1 were only significantly up or down-regulated
after prolonged treatment. Additionally, the expression of genes in cluster 2 and
cluster 4 were gradually increased or declined over time. To estimate the function
relevance to DC development, TGF-β1 regulated genes were further subjected to gene
set enrichment analysis. We found that TGF-β1 induced genes were enriched in gene
ontology (GO) categories related to immune cell activation and differentiation, antigen
presentation and signal transduction. On the contrary, TGF-β1 down-regulated genes
were involved in nucleic acid and amino acid metabolism and cell cycle control, which
also relates to the DC differentiation promoting activity of TGF-β1. Analogous to the
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observation based on PCA, these results provided further support to the notion that
TGF-β1 promotes DC commitment and differentiation.
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Figure 3.1.6: Gene expression kinetics regulated by TGF-β1 in CDPs.
A total of 3758 TGF-β1 regulated genes were identified by comparing untreated and
treated samples and were further classified by Fuzzy c-means into 6 clusters. Genes
in each cluster show a similar gene expression kinetics to TGF-β1. Clusters 1, 4
and 5 include down-regulated genes. Clusters 2, 3 and 6 reveal up-regulated genes
by TGF-β1 treatment. The number of genes in each cluster and selected genes are
shown.
Given the instructive role of transcription factors in DC commitment and subset spec-
ification, we further focused on transcription factors regulated by TGF-β1. The in-
duction of a cDC-like transcription profile in TGF-β1 treated CDP was observed by
hierarchical clustering analysis (Figure 3.1.7a). cDC specific transcription factors, such
as Id2, members of NF-kB signaling pathway (Nfkb1, Nfkb2, Nfkie, Relb and Rel),
were highly expressed in TGF-β1 treated CDP. Interestingly, the expression of pDC
affiliated transcription factors, such as Notch1, was down-regulated by TGF-β1 similar
to the MPP related genes Myb, Myc and Gfi1. These results were further supported
by RT-PCR analysis (Figure 3.1.7a; in collaboration with Piritta Felker, Institute for
Biomedical Engineering - Cell Biology, RWTH Aachen University, Aachen, Germany).
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Taken together, TGF-β1 accelerates DC differentiation within 24h by inducing a DC
affiliated transcription profile. Moreover, TGF-β1 functions on the bifurcation point
of DC subset specification and promotes cDC differentiation at the expense of pDC
development.
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Figure 3.1.7: Transcription factors involved in TGF-β1 signaling and DC
development.
(a) Transcriptional factors involved in TGF-β1 signaling and DC development selected
from TGF-β1 regulated genes were subjected to hierarchical clustering and represented
in heat map format. Genes that were highly up-regulated upon TGF-β1 treatment
after 24h and abundantly expressed in cDC are indicated (box). (b) RT-PCR anal-
ysis of selected genes shown in a (in collaboration with Piritta Felker, Institute for
Biomedical Engineering - Cell Biology, RWTH Aachen University, Aachen, Germany).
“C” indicates control.
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3.2 Dynamic Epigenetic Chromatin Signature and
Cis-Regulatory Network Control Dendritic Cell
Development
3.2.1 Epigenetic Modification
Emerging evidence shows that epigenetic mechanisms are critical in regulating cellular
homeostasis and development (Cui et al., 2009; Mikkelsen et al., 2007). The epigenetic
landscape governs the transcriptional programs that define the molecular foundations
of pluripotency, differentiation and reprogramming in stem cells (Azuara et al., 2006;
Bernstein et al., 2006). Histone modification is one of the most important epigenetic
pathways. The basic unit of chromatin is the nucleosome, consisting of 146 bp chro-
mosomal DNA wrapped around two copies of four core histone proteins (i.e., H2A,
H2B, H3 and H4). Nucleosomes can be covalently modified by chromatin modifying
complexes, resulting in histone tail and globular domain modifications (Tollervey and
Lunyak, 2012). Such post-translational modifications of histones control chromatin
structure and DNA accessibility and further lead to the regulation of gene expression.
Recent studies suggest that histone modifications directly correlate with gene tran-
scription (Bannister and Kouzarides, 2011; Zhou et al., 2010). For example, H3 lysine
4 (H3K4) and lysine 27 (H3K27) trimethylation at gene promoters are associated with
gene activation and repression, respectively. Many key developmental genes have biva-
lent modification that consists of both H3K4me3 and H3K27me3 marks in embryonic
stem cells (ESC). These genes are poised for either activation or repression during the
differentiation of ESC (Bernstein et al., 2006). Epigenetic modification also regulated
haematopoiesis (Abraham et al., 2013). Wei and his colleagues (Wei et al., 2009)
demonstrated that histone modifications controlled the specificity and plasticity in T
cell linage fate determination. Wong et al. (Wong et al., 2011) showed that gene ex-
pression during terminal erythropoiesis were mediated by distinct epigenetic changes.
However, the regulatory function of histone modifications and the interplay between
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them remain to be investigated in the context of DC development.
3.2.2 Global Map of Histone Modification in DC Develop-
ment
To understand the regulatory mechanism of DC fate decision, we utilized our DC
differentiation system (Felker et al., 2010) to obtain enough cells for the genomic anal-
ysis. The genome-wide maps of three histone modifications (H3K4me3, H3K27me3,
H3K9me3) were generated by ChIP-seq method for MPP, CDP, cDC and pDC. Figure
3.2.1a illustrates the chromatin state of key DC developmental genes upon DC devel-
opment. For examples, Gfi1 was previously identified as a MPP-specific gene, which
was highly expressed in MPP and was further down-regulated in CDP and DCs. Ac-
cordingly, Gfi1 showed a significant decrease of H3K4me3 level during the transition
from MPP to CDP, leading to the reduction of gene expression. It was further si-
lenced in DCs due to the enrichment of H3K27me3 or bivalent modification in the
gene promoter. cDC specific gene Id2 exhibited a particularly high level of H3K4me3
and a low level of H3K27me3 in cDC, whereas pDC affilicated gene Irf8 showed the
highest enrichment of H3K4me3 in pDC. These data indicated that the lineage-specific
histone marks correlated with the gene expression of key developmental genes in DC
development.
In total, 45,986 unique histone modification peaks (i.e., 26,220 H3K4me3, 42,667
H3K27me3 and 23,298 H3K9me3 peaks) were identified across four investigated cell
populations. Our data showed good agreement with previously published profiles
(Figure 3.2.2a). Of all H3K4me3 peaks in cDC, over 95% can be found in published
GM-DC (Granulocyte macrophage colony stimulating factor (GM-CSF) induced, bone
marrow derived DC, Garber et al. 2012). Additionally, the ChIP-seq signal of several
key DC regulators was validated by ChIP-PCR (Figure 3.2.2b; in collaboration with
Heike Chauvistre´, Institute for Biomedical Engineering - Cell Biology, RWTH Aachen
University, Aachen, Germany).
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Figure 3.2.1: Chromatin modification profiling of DC lineage commitment
and specification.
(a) H3K4me3, H3K27me3, H3K9me3 modifications and gene expression patterns at
Gfi1, Flt3, Id2, PU.1(encoded by Sfpi1) and Irf8 loci, in MPP, CDP, cDC and pDC.
(b) Hierarchical clustering analysis of histone modifications for all genes in four in-
vestigated cell types. Repressive marks H3K27me3 and H3K9me3 cluster together
and are separated from active marker H3K4me3. (c) The genome-wide distribution
of different modifications. The number of peaks across promoter, exon, intron, 3’ end
and intergenic regions were calculated for each modification. The bar plot shows the
fraction of peaks in each genomic region for each modification in MPP, CDP, cDC and
pDC.
Clustering analysis of all peak signals showed that the major epigenetic changes took
place during DC lineage specification (Figure 3.2.1b). The repressive marks (i.e.,
H3K9me3 and H3K27me3) were correctly clustered together and were separated from
active mark H3K4me3. As expected, H3K4me3 was mainly associated with promoter
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Figure 3.2.2: ChIP-seq and ChIP-PCR data of DC genes.
(a) H3K4me3 and H3K27me3 profiles at PU.1 (encoded by Sfpi1) locus are depicted.
Peak regions identified in our data (cDC) and data from public domain (GM-DC
and CD11c+ DC from GSE36104 and GSE25688, respectively) are indicated (gray
box). (b) ChIP-PCR analysis of histone modifications at promoters of Gfi1, Flt3,
Id2, PU.1 and Irf8 that shows moderate agreement with the respective ChIP-seq data
shown in Figure 3.2.1a (in collaboration with Heike Chauvistre´, Institute for Biomed-
ical Engineering - Cell Biology, RWTH Aachen University, Aachen, Germany). The
corresponding gene expression was shown.
regions in all four cell types analyzed (Figure 3.2.1c). H3K9me3 and H3K27me3 peaks
were predominantly confined to intergentic regions. Interestingly, the repressive mark
H3K27me3 in promoter regions was gradually enriched when MPP differentiated into
DC, reflecting the increasingly restricted gene expression repertoire during DC com-
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mitment and differentiation.
Although the genomic distributions of H3K4me3 peaks were rather conservative across
the DC development, the fraction of lineage-specific H3K4me3 peaks increased from
6.7% in progenitors to over 10% in DCs, indicating that acquisition of H3K4me3 may
activate DC specific genes and drive the differentiation (Figure 3.2.3). Conversely, a
significant decrease of lineage-specific H3K27me3 peaks were observed from MPP to
its downstream progenies, suggesting that reduction of repressive marks in CDP may
control and promote the transcriptional programme of DC lineages (Figure 3.2.3).
Collectively, our ChIP-seq data of histone modifications showed good quality and pro-
vided the basis of investigating the underlying epigenetic regulation upon DC lineage
commitment and specification.
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Figure 3.2.3: Distribution of lineage-specific histone modifications in pro-
moter and distal regions.
Lineage-specific H3K4me3 (up) and H3K27me3 (bottom) peaks are depicted in pro-
moter regions (i.e., TSS +/- 1kb; black) and distal regions (i.e., any regions outside
gene promoters; gray) and are shown in percentage of all identified peaks.
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3.2.3 Correlation Between Histone Modification and Gene
Expression
The correlation between histone modifications and transcriptiome profiles were also
analyzed. In general, the signal of histone modifications was characterized by calcu-
lating the average tag density in 2kb interval centered around transcription start site
(TSS) and 3’ end for each Refseq annotated gene. The signal of H3K4me3, H3K9me3
and H3K27me3 of MPP, CDP, cDC and pDC were compared with DNA microarray
data from the equivalent cell populations (Figure 3.2.4). H3K4me3 was found to as-
sociate with active promoters and gene transcription, i.e., genes with lower H3K4me3
levels tended to yield lower expression levels. It was consistent with the observations
in previous studies (Cui et al., 2009; Wei et al., 2009). In contrast, H3K9me3 and
H3K27me3 associated with inactive genes, as expected (Weishaupt et al., 2010). Ad-
ditionally, H3K27me3 marks in 3’ ends also shown apparent negative correlation with
gene expression.
Surprisingly, H3K9me3 at 3’ gene ends was associated with genes expressed at inter-
mediate or high levels, in particularly in cDC and pDC (R = 0.75 and R = 0.62, re-
spectively; Figure 3.2.4a). Such correlation was opposite to the correlation observed in
the promoter regions. It became higher when only differentially expressed genes of DC
development were taken into consideration, indicating that H3K9me3 modification at
gene 3’ ends might be involved in regulating DC developmental genes. (Figure 3.2.4b).
To further explore this observation, H3K9me3 signals were examined in larger re-
gions, comprising 10kb intervals centered around TSS and 3’ ends, respectively (Figure
3.2.5a). In comparison to lowest expressed genes (blue), the highest expressed genes
(red) showed an over-representation of H3K9me3 at gene 3’ ends in all four cell popu-
lations analyzed. As shown in Figure 3.2.5b, the progenitor associated gene Gfi1 had
an enrichment of H3K9me3 mark at 3’ end in MPP and CDP but not in DCs, whereas
cDC or pDC affiliated genes, such as Id2 and Il7r, exhibited higher H3K9me3 levels in
respective DC subsets in comparison to their progenitors. H3K9me3 is generally con-
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Figure 3.2.4: Correlation of histone modifications and gene expression.
The levels of H3K4me3, H3K27me3 and H3K9me3 modifications at gene promoters
(TSS +/- 1kb) or 3’ ends (TES +/- 1kb) were determined for all genes in MPP, CDP,
cDC and pDC. For each cell type genes were grouped into bins of 100 genes based
on their expression levels in descending order. The histone modification levels were
then averaged for the same bins of 100 genes and depicted in heat map format for (a)
all genes and (b) differentially expressed genes. Dark colors represent high levels of
modification; light or white colors indicate low or no modification. The corresponding
correlation coefficient values between histone modification levels and gene expression
levels are shown in bar plots. The dashed lines correspond to correlation coefficients
of 0.5 and -0.5.
sidered as a repressive mark and is associated with compacted chromatin (Hirabayashi
and Gotoh, 2010; Weishaupt et al., 2010). However, the presence of H3K9me3 was
observed in the promoters of highly expressed cancer-associated genes (Wiencke et al.,
2007), which indicated additional function of H3K9me3. Recent analysis on H3K9me3
also suggested its functional association with transcription elongation (Vakoc et al.,
2005). Taken together, our analysis demonstrated that the H3K9me3 marks occurred
at 3’ ends of active genes, and supported the notion that H3K9me3 may play active
role in transcriptional regulation of DC development.
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Figure 3.2.5: H3K9me3 modifications at gene end positively correlate with
gene expression.
(a) Average density plot of H3K9me3 modification across 10 kb region centered by
TSS or 3’ gene ends in MPP, CDP, cDC and pDC. Red solid line indicates the average
H3K9me3 signal of 2000 highest expressed genes in corresponding cell types; blue solid
line the average signal of 2000 lowest expressed genes; black dot line the average signal
of entire genome genes. (b) H3K9me3 modification patterns of Gfi1, Id2 and Il7r
in each investigated cell types are depicted. The peaks located at 3’ gene end are
highlighted using gray background. The mRNA levels of each gene are depicted in
heat map. Red represents high expression and blue low expression.
3.2.4 Stage-Specific Histone Marks Control DC Transcrip-
tional Program
It has been observed that specific histone modifications control gene expression (Berger,
2002; Heintzman et al., 2009; Zhang et al., 2012). To determine how epigenetic marks
related to gene expression in DC differentiation, we investigated how H3K4me3 and
H3K27me3 marks related to stage-specific gene expression in MPP, CDP, cDC and
pDC (Figure 3.2.6, see Results 3.1.4 for details of identification of the stage-specific
genes). The active mark H3K4me3 in MPP and CDP was confined to progenitor
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genes, while the same genes showed the repressive mark H3K27me3 in cDC and pDC.
For example, hematopoietic stem cell genes such as Myc, Id1, Taf4b and Cebpb are
transcription factors that were classified into MPP/CDP cluster (Figure 3.2.6a). They
showed an abundance of H3K4me3 and the absence of H3K27me3 marks at gene pro-
moters in MPP and CDP, in line with the transcription activation in the progenitor
cells. Upon development, these genes exhibited the loss of H3K4me3 and the gain of
H3K27me3 that resulted in gene silencing in DCs. Conversely, H3K4me3 mark in cDC
and pDC was observed for DC genes, while H3K27me3 mark was found for these gene
in progenitors.
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Figure 3.2.6: Gene expression, H3K4me3 and H3K27me3 occupancy in DC
development.
(a) mRNA expression (i.e., mRNA), signals of H3K4me3 and H3K27me3 marks in
the gene promoter (i.e., TSS +/- 1kb) of each differentially expressed gene upon DC
development (as in Figure 3.1.3a) are shown in heat map format. These genes were
classified into MPP/CDP, MPP, CDP, pan-DC(i.e., DCs), cDC and pDC clusters on
the basis of their expression levels as indicated in Figure 3.1.3b. The cells in these heat
maps are color-coded using a continuous color spectrum, from blue or white (i.e., lowest
expression or histone level) to red or dark colors (i.e., highest level). Key regulatory
factors of each cluster are listed. (b) For each of six clusters, mRNA expression,
H3K4me3 and H3K27me3 occupancy were calculated using the geometric mean of the
levels of respective genes and are shown in heat map format. Color code as in (a).
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We have previously demonstrated that CDP acquired a DC-primed expression pro-
file during the development (Figure 3.2.6b; see Results 3.1.3 for details). For instance,
pan-DC related genes showed prominent up-regulation from MPP to CDP, while MPP-
specific genes displayed significantly down-regulation during the DC commitment. The
heat map of histone modifications revealed that these DC-primed gene expression pat-
terns in CDP were associated with DC-primed epigenetic signatures (Figure 3.2.6b).
3.2.5 CDP Exhibits DC-Primed Epigenetic Profiles
To examine the dynamics of epigenetic modifications during DC commitment, H3K4me3
and H3K27me3 were used to classify gene promoters into four categories, includ-
ing H3K4me3-only modified genes, H3K27me3-only modified genes, H3K4me3 and
K3K27me3 bivalent modified genes and genes without any of these modifications.
During the DC commitment, histone modification marks remained largely stable (i.e.,
9925 H3K4me3 genes, 1512 H3K27me3 genes and 2609 bivalent genes common to MPP
and CDP; Figure 3.2.7a-c). However, 345 genes with H3K4me3 marks from MPP to
CDP resulted in the up-regulation of their expression. These genes were found to be
preferentially enriched in GO terms such as immune response, leukocyte activation and
cell activation, indicating that H3K4me3 activated DC related genes in CDP (Figure
3.2.7d).
Recent studies suggest that bivalent modification is of importance in the regulation of
ESC and early hematopoietic development (Bernstein et al., 2006; Weisenberger et al.,
2002). During DC commitment, a set of 680 early developmental-related genes that
were uniquely bivalent modified in MPP were resolved to ‘monovalent’ or no mod-
ification in CDP (Figure 3.2.7e). This suggested that MPP specific-genes might be
escaped from poised expression to activation or repression in CDP. On the other hand,
the gain of bivalent modifications seemed to be associated with the repression of gene
expression in CDP and cDC. (Figure 3.2.7c). These results indicated that bivalent
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Figure 3.2.7: Changes of epigenetic modifications between MPP and CDP.
(a-c) Venn diagrams of H3K4me3, H3K27me3 and bivalent marked promoters between
MPP and CDP are shown, respectively. The non-overlapping portions of each venn
diagram indicates the sets of genes showing gain or loss of histone modifications upon
DC commitment. The mRNA expression of these genes is shown in box plots using
microarray data of MPP, CDP, cDC and pDC. Different significance levels are indicated
by stars, i.e., ∗, p-value < 0.05; ∗∗, p-value < 0.005; ∗ ∗ ∗, p-value < 0.0005. (d)
Enriched gene ontology terms in genes that showed gain of H3K4me3 from MPP to
CDP as indicated (a). (e) Enriched gene ontology terms in genes that showed loss of
bivalency from MPP to CDP as indicated (c).
modification might be also involved in regulating DC commitment.
To further extend our observation, we focused on the differentially expressed genes
during the transition of DC commitment (i.e., from MPP to CDP). The genes up-
regulated in CDP showed significant increase of H3K4me3 and decrease of H3K27me3,
suggesting gene activation (Figure 3.2.8). Interestingly, such abundance of H3K4me3
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Figure 3.2.8: Epigenetic regulation of differentially expressed genes be-
tween MPP and CDP.
The expression levels of 429 differentially regulated genes between MPP and CDP
(left) and the ChIP signal of H3K4me3 and H3K27me3 marks at promoter regions
(right) are reported in box plots.
or depletion of H3K27me3 were epigenetically inherited to cDC and pDC. Analogously,
changes of H3K4me3 and H3K27me3 that were passed to DCs were associated with
down-regulation of genes in CDP.
Furthermore, Figure 3.2.9a, b showed that CDP displayed the H3K4me3 and bivalent
modification patterns primed to DCs. For instance, Cd34, an early hematopoietic
marker, showed a significant decrease of H3K4me3 marks from MPP to CDP that
were further resolved into bivalent modifications (Figure 3.2.9c). In contrast, Cd74,
encoding HLA-DR antigens-associated invariant chain, showed a prominent increase
of H3K4me3 marks during DC commitment. Its expression was further up-regulated
in DCs due to the accumulation of H3K4me3 (Figure 3.2.9c). Taken together, the
lineage-specific genes were regulated by a DC-primed epigenetic pattern of H3K4me3
and bivalency in CDP during DC commitment.
The epigenetic regulation of different modifications was also observed upon DC sub-
set specifications. Figure 3.2.10a revealed that the change of H3K4me3 and bivalent
modifications were associated with gene expression changes between two DC subsets.
For example, cDC highly expressed genes, such as c-Kit and Batf3 (Hildner et al.,
2008) displayed high levels of H3K4me3 and low levels of H3K27me3 in cDC. Their
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Figure 3.2.9: H3K4me3 controls gene expression during DC commitment.
(a) The distributions of H3K4me3-only, H3K27me3-only, bivalent modified and no
modified genes in up-regulated (i.e., high expressed genes in CDP compared to MPP)
and down-regulated genes (i.e., high expressed in MPP) are shown in percentages. (b)
The distribution in entire genome genes is reported. (c) The H3K4me3 and H3K27me3
modification patterns are shown for Cd34 and Cd74 genes as examples. In addition,
their mRNA expression profiles are given.
expression was repressed in pDC due to the bivalent modifications at promter regions
(Figure 3.2.10b). Similarly, pDC-specific gene Pacsin1 (Miller et al., 2012) showed
H3K4me3 abundance in pDC and bivalent domain in cDC (Figure 3.2.10b), leading
to lineage-specific gene expression.
In conclusion, the analysis of epigenetic dynamics in hematopoietic stem/progenitor
cells and DC progeny suggested that CDP exhibit a DC-primed epigenetic profile of
H3K4me3 and bivalent modification during DC commitment. The changes of histone
modifications upon cellular state transitions optimize the expression of lineage-specific
genes that further drive DC specifications.
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Figure 3.2.10: H3K4me3 and bivalent modification control gene expression
during DC subset specifications.
(a) The distributions of H3K4me3-only, H3K27me3-only, bivalent modified and no
modified genes in up-regulated (i.e., high expressed genes in cDC compared to pDC)
and down-regulated genes (i.e., high expressed in pDC) are shown in percentages.
(b) The H3K4me3 and H3K27me3 modification patterns are shown for three exem-
plary genes (i.e., c-Kit, Batf3 and Pacsin1). Bivalent domains are highlighted in gray
background. In addition, their mRNA expression profiles are given below.
3.2.6 The Instructive Role of PU.1 in DC Development
PU.1 is known as a master regulator in haematopoiesis with a prominent role in mul-
tiple cell fate decisions including DC development (Carotta et al., 2010; Scho¨nheit
et al., 2013). To illustrate the instructive role of PU.1 in DC lineage determination,
the genome wide PU.1 binding profiles were generated by ChIP-seq method for MPP,
CDP, cDC and pDC (in collaboration with Heike Chauvistre´, MSc, and Kristin Sere´,
PhD, Institute for Biomedical Engineering - Cell Biology, RWTH Aachen University,
Aachen, Germany.). The principal component analysis of these PU.1 binding pro-
files and publicly available PU.1 data from multiple hematopoietic lineages revealed
three distinctive development trajectories from hematopoietic progenitor cells (MPP)
towards either erythroid or T/B or DC compartment (Figure 3.2.11a). Interestingly,
CDP were clustered with DCs (i.e., cDC, GM-DC and pDC) and were distant from
MPP, indicating that CDP exhibited DC-primed PU.1 binding profiles. Compared to
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pDC, cDC and GM-DC were positioned very close to CDP, which supported the no-
tion that differentiation of cDC might be the default DC development pathway (Belz
and Nutt, 2012; Ghosh et al., 2010).
Figure 3.2.11: PU.1 transcription factor binding in DC development.
(a) Principal component analysis of genome-wide PU.1 binding profiles in MPP, ery-
throid progenitor cells (EP), T/B lymphoid cells (double negative T cells, DN; pro B
cells, ProB), DC progenitors and subsets (CDP, cDC and pDC; GM-CSF derived DC;
GM-DC). The DC cluster is highlighted and enlarged. (b) The genomic distribution of
PU.1 peaks in DC progenitors and subsets. Promoter, TSS +/- 1kb; 3’ end, TES +/-
1kb. (c) PU.1 binding peaks were classified by active enhancer (yellow), poised en-
hancer (orange) and active promoter in MPP, CDP and cDC (red). The enhancer and
promoter annotations were obtained from ChIP-seq analysis of GM-DC (GSE36104).
The genomic distribution of PU.1 suggested that it primarily bound to gene bodies and
intergenic region in hematopoietic stem/progenitor cells (i.e., MPP and CDP) and DCs
(Figure 3.2.11b). This was consistent with the observations in previous studies (Gar-
ber et al., 2012; Heinz et al., 2010). It also indicated that PU.1 can potentially bind to
distal cis-regulatory elements, such as enhancers. Moreover, a prominent increase of
PU.1 binding events was observed in the promoter region from MPP to CDP and cDC
(Figure 3.2.11b). About 60% and 74% of PU.1 peaks in CDP and cDC were found
in active promoter, active enhancer and poised enhancer regions of GM-DC, which
were significantly enriched compared to those in MPP (only 24%) (Figure 3.2.11c).
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These results suggested that PU.1 played a positive role in DC lineage commitment.
In addition, cDC and pDC showed apparent difference in PU.1 occupancy, indicating
that PU.1 might be also involved in the regulation of DC lineage diversification.
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Figure 3.2.12: Changes of PU.1 occupancy during DC development.
The differential PU.1 peaks between MPP and CDP (a) and between cDC and pDC
(b) are depicted in scatter plots. The differential PU.1 peaks are indicated in blue
and red. The non-differential peaks are colored in gray. The numbers of differential
and non-differential peals are indicated. The de-novo PU.1 motifs calculated using
cell specific peaks (i.e., MPP, CDP, cDC and pDC peaks) are shown below. (c) PU.1
target genes in differentially regulated genes between progenitors (i.e., MPP vs. CDP)
and between DC subsets (i.e., cDC vs. pDC) are shown in percentage (blue bars).
Furthermore, the proportion of PU.1 target genes in entire genome genes was used as
background control (white bars). The Fisher’s exact test was applied to calculate the
enrichment of PU.1 targets. The significance level increases with the number of stars
shown above the bars.
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The differences of PU.1 occupancy during DC development are illustrated in Figure
3.2.12a, b. A total of 19,944 MPP and 23,054 CDP-specific peaks were detected
upon lineage commitment. These CDP peaks revealed a conventional PU.1 motif
that contained a ETS domain (i.e., GGAA core site), whereas MPP peaks produced
an alternative de-novo motif (Figure 3.2.12a). Analogously, a large number of PU.1
peaks were observed to be differential bound in cDC and pDC (Figure 3.2.12b). The
de-novo motifs that were generated by cDC and pDC peaks resembled a classic PU.1
motif, indicating that PU.1 target genes may play important roles in DC specification
and determination of cDC or pDC identities. In line with the observation of de-novo
motifs, we found that the binding of PU.1 was significantly associated with the tran-
scriptional activation of lineage specific genes in CDP, cDC and pDC (Figure 3.2.12c).
This demonstrated the positive roles of PU.1 in regulating DC lineage fate determi-
nation. In addition, PU.1 might be also involved in the transcriptional repression of
stem cell-related genes or early hematopoietic genes in MPP and it progeny (Figure
3.2.12c). Taken together, our analysis suggested that differential binding of PU.1 reg-
ulated DC development by controlling DC lineage-specific genes.
3.2.7 Identification of PU.1 Co-Binding Transcription Factors
The differentiation of hematopoietic stem cells into distinct lineages is controlled by
a complex transcription factor network. It has been demonstrated that PU.1 defines
the macrophage and B cell identities by cooperating with different cell type-restricted
transcription factors (Heinz et al., 2010). It is conceivable that DC development is
regulated by the interactions between PU.1 and DC lineage-specific TFs . To identify
key PU.1 co-binding partners during DC commitment and specification, we designed
an integrative computational approach to analyze PU.1 binding profiles and gene ex-
pression data (See Methods, 2.2.5 for details, in collaboration with Dr. Ivan Gesteira
Costa Filho, IZKF Research Group Computational Biology, RWTH Aachen Univer-
sity, Aachen, Germany). Briefly, we focused on the differentially expressed TFs upon
DC development and collected their sequence motifs from public databases. The pu-
tative TF binding sites were then detected by performing motif search within PU.1
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differential peaks close to differently expressed genes. Finally, one-tailed Fisher’s exact
test was applied to measure the enrichment of TF binding sites, in order to identify
PU.1 co-binding partners.
Figure 3.2.13: Identification of lineage-specific PU.1 co-binding transcrip-
tional factors.
(a) Heat map reports the enrichment of transcription factor motifs (row) in MPP,
CDP, cDC and pDC (column). P values are plotted and color-coded using a continu-
ous spectrum from gray (p-value ≥ 0.05) to blue (p-value < 0.05). A total of 20 TFs
(27 motifs) that were considered as potential PU.1 co-binding partners are labeled in
red. (b) PU.1 binding profiles are shown for Id2 and Irf1 loci in MPP, CDP, cDC and
pDC. Differential PU.1 peak regions are highlighted in gray background. Green lines
indicate transcription factor binding sites (TFBS) predicted inside differential PU.1
peak regions.
Figure 3.2.13a illustrated 27 TFs (31 TF motifs) that were significantly enriched. On
the basis of gene expression patterns, 20 TFs including PU.1 itself (labelled in red
in Figure 3.2.13a) were considered as the potential PU.1 partners during the course
of DC development. For example, interferon regulatory factors (Irf8) and the Ets-
domain transcription factor (i.e., Spib) are known regulators of DC differentiation.
Irf8-deficient mice lack many mature DC subsets (Belz and Nutt, 2012). Spib is also
indispensable in DC development, particular in pDC (Nagasawa et al., 2008). Both
factors showed a significantly enrichment in MPP, CDP and two DC subtypes indi-
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cating that they formed composite binding with PU.1 in each step of DC development
(Cluster I in Figure 3.2.13a).
Upon DC commitment step, a panel of TFs, such as Stat1, Klf4, Irf1, Runx1, Irf4, Est1
and Egr1, was enriched in CDP (Cluster II in Figure 3.2.13a), indicating that PU.1
initiated the DC program by recruiting or cooperating with multiple DC regulators.
As an example, the up-regulation of Id2 expression was accompanied by the increase
of PU.1 binding occurring in its promoter from MPP to CDP (Figure 3.2.13b). Within
this PU.1 binding region, Irf8, Klf4 and Egr1 binding sites were detected, suggesting
that these factors may be orchestrated by PU.1 to promote Id2 expression.
Upon DC specifications, PU.1 collaborated with distinct sets of factors to restrict the
development program towards to either cDC or pDC, such as Rel/Rela/Nfkb1 and Irf5
for cDC and Tcf4/E2-2 for pDC (Cluster III, IV, VI in Figure 3.2.13a). Compared
to pDC, the cDC marker Id2 was exclusively bound by PU.1 at several promoter or
distal regions, where binding sites of Jun/Ap1, Rel/Nfkb and abovementioned Irf8,
Klf4, Egr1 were found (Figure 3.2.13b). Conversely, pDC-afflicated gene Irf1 occupied
by a lineage-specific PU.1 region that contains the bind sites of Tcf4/E2-2 (Figure
3.2.13b). This result indicated that the transcriptional activity of Irf1 was regulated
by the composite binding of PU.1 and Tcf4. Furthermore, many cDC or pDC specific
regulators identified in analysis were found to be enriched in CDP (Figure 3.2.13a),
such as Fos/Jun/Ap1 and Tcf4, supporting the notion of DC priming in CDP.
3.2.8 The Regulatory Circuitry of DC Development
To better understand the relationships among individual PU.1 co-binding factors,
four lineage-specific transcription factor regulatory networks were constructed (Fig-
ure 3.2.14). In each network, nodes represent the above-mentioned PU.1 co-binding
partners and selected key DC development regulators from literature (e.g., Flt3, Kit
and Id2 shown in white). An edge between two nodes indicates the process that a
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particular TF activates its target gene.
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Figure 3.2.14: Lineage-specific transcription factor regulatory networks.
Nodes represent identified PU.1 co-binding partners that are active (red) or inactive
(gray) in MPP, CDP, cDC and pDC. Eleven selected key DC development regulators
from literature (white) were also included in the analysis. A directed edge from node
a to node b (black) indicates that the binding site of node a is found in the differential
PU.1 peak region close to node b. A self-loop edge of a node represents auto-regulatory
feedback loop of the indicated transcription factor (highlighted in gray background).
The gray edges represent all possible regulatory links between any two factors.
Different topologies and connectivity density of four lineage-specific networks reflected
that how dynamics of PU.1 composite binding drive DC development. Upon lineage
commitment, PU.1 recruited a core set of TFs (i.e., Irf8, Klfr, Runx1, Egr1 and Stat1)
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to activate the expression of DC marker genes (e.g., Id2, Csf1 and Tcf4) in CDP (up-
per right panel in Figure 3.2.14). Upon specification, the DC subtype-specific TFs
collaborated with PU.1 to define cDC or pDC identity (two bottom panels in Fig-
ure 3.2.14). For instance, Rel/Nfkb and Irf4 exclusively co-bound with PU.1 in cDC,
whereas Tcf4, Ets1, Irf1 and Spib only cooperated with PU.1 in pDC.
The auto-regulatory feedback loops are the important building blocks in transcrip-
tional regulatory networks (Kie lbasa and Vingron, 2008; Kueh et al., 2013). PU.1 was
previously observed to control hematopoietic development by forming auto-regulatory
loops (Leddin et al., 2011; Okuno et al., 2005). Intriguingly, several positive auto-
regulatory loops of key DC developmental genes (highlighted in gray background)
were captured in the networks (Figure 3.2.14). For example, the self-loop edge of Irf8
in CDP indicated that Irf8 was able to regulate its transcription during commitment,
which led to the increase of Irf8 expression. Moreover, Irf8 showed an extremely high
concentration and was required in pDC development (Tsujimura et al., 2003). In line
with these observations, Irf8 was found to form auto-regulatory loop in pDC. Similar-
ily, such self-regulation was also observed in cDC marker Irf4 upon cDC development.
To decipher the complexity of DC transcriptional regulation, a DC regulatory circuitry
were generated by integrating abovementioned four lineage-specific TF networks (Fig-
ure 3.2.15). Each regulator in the circuitry was positioned in a particular stage of DC
development in which it was involved. Additionally, the positive or negative interac-
tions between regulators on the basis of literatures were included. For example, PU.1
was also observed to inhibit Gata1/2 activation, which led to the specific myeloid cell
fates (Walsh et al., 2002; Zhang et al., 1999). Accordingly, this inhibition of Gata2 by
PU.1 was displayed in the circuity.
Figure 3.2.15 demonstrated that PU.1, as a central hub of the network, positively
interacted with early hematopoietic regulators (e.g., Gfi1 and Cebpa) and DC related
factors (e.g., Irf family genes). During DC commitment, PU.1 coordinated a genetic
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Figure 3.2.15: The regulatory circuitry of DC development.
The network illustrates the organization of integrated DC regulatory circuitry. Nodes
represent key regulatory factors involved in DC development. A directed edge from
factor a to factor b indicates an activating (green) or inhibiting (red) function of factor
a to factor b.
programme including Irf8, Runx, Klf4, Irf5, Egr1, Flt3 and Stat1/3 to establish and
maintain DC lineage fate. Additionally, it is also conceivable that PU.1 restricted MPP
to DC lineage pathway by directly or indirectly inhibiting other lineage makers (e.g.,
Gata2 and Tal1). After commitment, CDP can undergo two different developmental
pathways that facilitate lineage diversification. These two antagonized pathways were
controlled by respective DC subset-specific factors. For example, the high expression
of cDC marker Id2 inhibits pDC gene Tcf4 and vice versa (Cisse et al., 2008; Li et al.,
2012). Furthermore, the positive auto-regulatory feed loops observed in Gfi1, PU.1,
Irf8, Klf4, Irf4 and Tcf4 provided the basic regulatory mechanisms that stabilized DC
developmental programme and facilitated DC lineage differentiation.
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3.3 DNA Methylation Changes Determine Aging
of Blood
3.3.1 Epigenetics and Aging
Aging reflects accumulation of cellular changes either due to stochastic defects or due
to a regulated developmental process (Garinis et al., 2008). This process is usually
measured chronologically although it does not perfectly correlate with time. Many
parameters, such as genetic background, disease and life style have a great impact
on biological age. Several molecular biomarkers or methods have been developed to
estimate human age, including leukocyte telomere length, analysis of age-dependent
deletions of mitochondrial DNA and T-cell DNA rearrangements (Blasco, 2005; Meiss-
ner and Ritz-Timme, 2010). However, all of these biomarkers or methods have rel-
atively low precision, thus have practical limitations (Meissner and Ritz-Timme, 2010).
The concept of epigenetic landscape provides new perspectives for biomarkers. In
particular, DNA methylation (DNAm) is well known to change upon aging (Fraga
and Esteller, 2007). It has been demonstrated that age-related CpG sites (AR-CpGs)
are either hypermethylated or hypomethylated (Alisch et al., 2012; Bork et al., 2010;
Christensen et al., 2009; Fraga et al., 2005). These DNAm changes are enriched in
bivalent chromatin domain promoters and Polycomb group protein target genes, indi-
cating that they might be governed by a developmental process (Maegawa et al., 2010;
Rakyan et al., 2010; Teschendorff et al., 2010). It is still not unclear how epigenetic
modifications are regulated upon aging or if they reflect an increased deviation of lo-
cal DNAm levels due to loss of control at specific loci (Hannum et al., 2013). Some
CpG sites reveal almost linear DNAm changes upon aging and therefore can be used
for age-prediction (Bocklandt et al., 2011; Hannum et al., 2013; Koch and Wagner,
2011). Bocklandt et al. described a predictor of age for saliva samples generated on
DNAm profiles of 34 twin pairs, indicating that age-prediction based on few CpG sites
is feasible. However this has not been validated in an independent set of samples.
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In our study, we pooled publicly available DNAm profiles of blood samples to identify
AR-CpG sites which relate best to predict age of donors. Based on this analysis we
evolved an Epigenetic-Aging-Signature which only requires measurement of DNAm
levels at three CpG sites. Subsequently, we evaluated the performance of our age-
prediction model using pyrosequencing. This study was done in collaboration with
Carola Weidner and Wolfgang Wagner, Helmholtz Institute for Biomedical Engineer-
ing, Stem Cell Biology and Cellular Engineering, RWTH Aachen University Medical
School, Aachen, Germany.
GEO 
accession Reference Tissue Cell type Samples 
Age range 
(median)  
in years 
Gender 
(f/m) 
GSE19711 Teschendorff et al., 2010 blood leukocytes 261 
52 – 78 
261/0 
(64) 
GSE20242 Rakyan et al., 2010 blood CD14
+ 
monocytes 22 
16 – 69 
16/6 
(34) 
GSE20242 Rakyan et al., 2010 blood CD4+ T cells 18 
16 – 69 
13/5 
(29.5) 
GSE23638 Chen et al., 2011 blood lymphocytes 23 
2 – 35 
11/12 
(12) 
GSE20236 Rakyan et al., 2010 blood leukocytes 88 
49 – 74 
88/0 
(63) 
GSE27317 Adkins et al., 2011 cord blood MNCs 163 0 78/85 
Table 3.3.1: The DNAm profiles of blood cells.
The list of six data sets is shown. For each set the corresponding NCBI GEO accession
number, reference, the types of cell and the number of samples are reported. In
addition, the age range (and median age) is given. Furthermore, for each set the
number of samples taken from female (f) or male(m) is provided.
3.3.2 Age-related DNAm Changes in Blood Samples
We assembled 575 DNAm profiles of blood cells derived from four different studies
that spanned an age-range from 0 to 78 years (Table 3.3.1). All DNAm profiles were
generated using HumanMethylation27 BeadChip platform which covers 27,578 indi-
vidual CpG sites (Bibikova et al., 2009). AR-CpGs with linear DNAm changes upon
aging were determined by Pearson correlation (R > 0.85 or R < -0.85). A total of
102 CpG sites were identified that met the criterion, including 58 hypomethylated
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and 44 hypermethylated CpGs (Figure 3.3.1). We observed that the DNAm level of
58 AR-CpGs with negative correlation tended to decrease over age, whereas for 44
hypermethylatied CpGs, the DNAm level generally increased upon aging.
Figure 3.3.1: Age-related DNAm changes in blood samples.
Heat map of 102 AR-CpG sites derived from 575 DNAm profiles of blood cells from
different aged donors with R > 0.85 or R < -0.85.
Furthermore, the hypermethylated AR-CpGs were found to be associated with genes
involved in “hematopoietic regulation” indicating that these age-related DNAm changes
corresponded to tissue specificity. They were also flanked by GC-rich sequences (Fig-
ure 3.3.2a, b). Predicted transcription factor (TF) binding sites within 1 kb up- and
down-stream of AR-CpG sites differed considerably for hypo- and hypermethylated
loci (Figure 3.3.2c, d). Furthermore, only hypermethylated CpGs were significantly
enriched in regions with bivalent histone modifications in embryonic stem cells (ESC)
and H3K27-trimethylation (H3K27me3) in monocytes and mononuclear cells (Figure
3.3.3) (Ku et al., 2008; Pan et al., 2007) and this has also been described before
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(Rakyan et al., 2010; Zhu et al., 2013). Taken together, the underlying mechanism
that entails age-related DNAm changes at specific genomic regions seems to differ in
hypo- and hyper-methylated CpGs.
Motif TF Frequency ES P-value 
ZFP161 75% 1.45 0.001 
SMAD3 98% 1.18 0.003 
MYC-
MAX 48% 1.71 0.004 
NFKB1 84% 1.30 0.004 
SP4 100% 1.30 0.005 
Motif TF Frequency ES P-value 
OBOX2 41% 1.89 0.001 
MYF6 74% 1.37 0.001 
NR4A2 57% 1.50 0.002 
DMBX1 28% 1.87 0.008 
NR2F1 62% 1.35 0.01 
1 2 3 4 5 6 7 8 9 10111213141516171819202122
Position
0
0.2
0.4
0.6
0.8
1
Pr
ob
ab
ilit
y
1 2 3 4 5 6 7 8 9 10111213141516171819202122
Position
0
0.2
0.4
0.6
0.8
1
Pr
ob
ab
ilit
y
58 negatively correlated CpGs 44 positively correlated CpGs 
44 positively correlated CpGs 58 negatively correlated CpGs 
a b 
c d 
P
ro
ba
bi
lit
y 
Po ition 
-  -5 -10  5 10 P
ro
ba
bi
lit
y 
Po ition 
-  -5 -10  5 10 
Figure 3.3.2: Nucleotides frequency and enriched motifs near AR-CpGs.
In (a) and (b) The frequency of nucleotides next to CpG sites which are either hy-
pomethylated or hypermethylated upon aging is shown in a sequence logo plot, respec-
tively. The size of letter indicates the probability of each base at a specific location.
In (c) and (d), top five predicted transcription factor (TF) binding sites within 1 kb
up- or down-stream of negatively and positively correlated AR-CpGs are shown, re-
spectively. For each TF, its corresponding binding site motif and frequency is shown.
In addition, for each motif the enrichment score (ES) and p-value that was calculated
by Fisher′s exact test is reported.
Moreover, a multivariable linear model was trained to predict donor’s age based on the
102 AR-CpG sites. The predicted age correlated well with chronological age with a
mean absolute deviation (MAD) of only 3.34 years (Root Mean Square Error [RMSE]
= 4.26 years; R2 = 0.98; Figure 3.3.4). These AR-CpG sites were further validated in
three publicly available datasets on blood samples (Day et al., 2013; Horvath et al.,
2012; Lam et al., 2012) using the same multivariate linear model. The MAD from
chronological age in these datasets was only slightly higher (GSE37008: 4.02 years;
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Figure 3.3.3: Enrichment of histone modification markers near AR-CpGs.
ChIP-seq data for histone modifications (H3K4me3 and H3K27me3) of embryonic
stem cells (ESC; a, b), CD14+ monocytes (c), and mononuclear cells (MNC; d) were
matched to CpG loci represented on the HumanMethylation27 BeadChip platform.
Enrichment of histone modifications markers in age-related hypomethylation (blue)
or AR-hypermethylation (red) was determined in relation to all CpG sites on the
array (grey). AR-hypermethylation is significantly enriched in genomic regions, which
harbor bivalent domains in ESC and H3K27me3 modifications in hematopoietic cells.
Significance was calculated by Fisher′s exact test and indicated by single, double or
triple stars representing increasing level of significance.
GSE49904: 5.79 years; GSE41037: 5.52 years; Figure 3.3.5a-c). Furthermore, we have
considered the recently published data set of 656 DNAm profiles on blood samples
(aged from 19 to 101 years) (Hannum et al., 2013). This data set has been analyzed
on the HumanMethylation450 BeadChip that assays 485,577 CpG sites including 99 of
the 102 AR-CpG sites (Bibikova et al., 2011). When we applied the above mentioned
linear model, there was a clear correlation between predicted age and chronological age
(R2 = 0.71). However, the linear offset indicated a systematic bias which might be due
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to the three missing CpG sites or to the different assay design of the two microarray
platforms (Bibikova et al., 2011; Sandoval et al., 2011). Therefore, we adjusted a mul-
tivariate regression model that facilitated age predictions based on these 99 AR-CpG
sites similar to the above mentioned model (MAD: 4.12 years; RMSE: 5.34 years; R2
= 0.87; Figure 3.3.5d).
Figure 3.3.4: A multivariate linear model generated using 102 AR-CpG
sites.
On the basis of 102 AR-CpGs, a multivariate model was generated to predict donor
age and these predictions were compared to the corresponding chronological age. The
entire set of 575 samples was divided into a training set and a test set. Leave-one-out
cross-validation was applied to evaluate the performance of the model. The mean
absolute deviation (MAD) indicates prediction error.
3.3.3 AR-DNAm Changes Are Counteracted in Pluripotent
Stem Cells
We have recently demonstrated that senescence-associated (SA) DNAm changes, which
accumulate during long-term culture of cells in vitro, can be reversed by reprogram-
ming into induced pluripotent cells (iPSC) (Koch et al., 2012, 2013). Here, we analyzed
if AR-DNAm changes are also reversed in this data set upon reprogramming. Overall,
CpG sites which were hypermethylated upon aging were hypomethylated in pluripo-
tent cells and vice versa (Figure 3.3.6a). When the previously generated multivariate
linear model was applied, the ESC and iPSC were even predicted to be of negative
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Figure 3.3.5: Validation of AR-CpG sites based-linear model using inde-
pendent datasets.
(a-c) Three additional datasets (GSE37008, n=99, Lam et al. 2012; GSE49904, n=69,
Day et al. 2013 and GSE41037, n=687, Horvath et al. 2012) that are based on the
HumanMethylation27 BeadChip, were used for further validation of the multivariate
model (Figure 3.3.4). Age predictions based on 102 CpG sites underlined the pre-
cision and reproducibility of the model. (d) AR-CpG sites were further analyzed in
the dataset of Hannum et al (GSE40279, n=656, Hannum et al. 2013), which was
profiled using HumanMethylation450 BeadChip. Based on 99 of 102 CpG sites that
were presented in the data set, the predicted age clearly correlated with chronological
age (gray dots). However, the linear offset indicated a systematic bias which might
be due to the three missing CpG sites or to the different assay design of the two mi-
croarray platforms. A multivariate model based on the 99 CpGs of the 450k BeadChip
facilitated reliable age predictions (MAD: 4.12 years; black dots) indicating that these
CpGs are clearly age-associated.
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age (Figure 3.3.6b). These findings fit nicely to other recent observations that iPSC
generated from senescent cells or centenarian donors reset telomere length, gene ex-
pression profiles, and other physiological features of young cells (Lapasset et al., 2011;
Marion et al., 2009). In addition, our results indicated that iPSC are rejuvenated also
on the epigenetic level.
Figure 3.3.6: Age-related DNAm changes are reversed in iPSC.
(a) AR-CpGs were analyzed in MSC, iPSC generated from these MSC, and ESC using
heat map. In addition, cells were clustered by Euclidean distance. (b) ESC and iPSC
were predicted of negative age indicating that AR-DNAm changes are overall reversed
by reprogramming into pluripotent cells. Embryonic stem cells, ESC (orange); induced
pluripotent cells, iPSC (blue); Mesenchymal stem cells, MSC (green for early passage;
red for late passage).
3.3.4 Selection of the Epigenetic-Aging-Signature
Analysis of DNAm in a small subset of AR-CpGs might be sufficient for robust age
predictions. Restriction to the most relevant CpGs would facilitate site specific anal-
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Figure 3.3.7: Development of the Epigenetic-Aging-Signature.
(a) Selection scheme of Epigenetic-Aging-Signature. (b) Most relevant AR-CpGs were
selected by iterative resampling of 575 DNAm profiles into training and testing sets on
the basis of different split-ratios. Age-predictions were calculated on training sets using
either 51 AR-CpGs or subsets of 5 CpGs. Subsets with 5 CpGs that were selected by
RFE can facilitate age-predictions with mean absolute deviation from chronological age
of less than 6 years. (c) Relative frequency of top 10 AR-CpGs in the best performing
subsets of 5 CpGs. For example, the first two AR-CpGs occurred in ∼90% of all the
best subset.
ysis of DNAm instead of profiling approaches. Therefore, we developed a searching
strategy to find subsets of AR-CpGs that interplay best for age predictions (Figure
3.3.7a, see Methods 2.3.4 for details). AR-CpGs with the highest variation in DNAm
level were used for recursive feature elimination (RFE) to select subsets of five CpG
sites that were tested in multivariable linear regression models. Predictions for each
of these subsets were determined by iterative divisions of the sample set into training
and test sets on the basis of five different ratios, i.e., 50%:50%; 60%:40%; 70%:30%;
80%:20%; 90%:10%. For further analysis, only those subsets of 5 CpGs were considered
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that performed above average of models based on all 51 AR-CpG sites (Figure 3.3.7b).
From all successful feature selection runs, the frequency of occurrence of individual se-
lected CpGs was calculated. The top 10 most frequently selected CoG sites are shown
in Figure 3.3.7c. Five CpGs were found to occur in more than 50% of the success-
ful runs, indicating that they were of central importance for age-predictions (Figure
3.3.7c). These five CpG sites are associated with ectodysplasia A receptor associated
death domain (EDARADD) that has been associated with age-related DNAm changes
before (Bocklandt et al., 2011); integrin, alpha 2b (ITGA2B); small GTP-binding pro-
tein RAB36; phosphodiesterase 4C (PDE4C); and aspartoacylase (ASPA) .
3.3.5 Validation of the Epigenetic-Aging-Signature
DNAm at top-5 AR-CpG sites was subsequently analyzed by pyrosequencing after
bisulfite conversion (see Methods 2.3.5 for details). However, the sequences in the
vicinity of cg09809672 (EDARADD) and cg15379633 (RAB36) were not ideal for the
primer design and therefore we focused on the remaining three AR-CpGs. The cor-
responding CpG probe sequences are shown in Figure 3.3.8a. Initially, a training set
of 82 samples was used for depicting a clear age-associated correlation for each of the
three CpGs. In fact, the upstream located CpG site of cg17861230 (PDE4C) that was
covered by the same pyrosequencing assay, revealed an even better age-association and
was therefore considered for further analysis (Figure 3.3.8a, b). A multivariable linear
regression model based on these pyrosequencing results facilitated age-predictions with
a MAD from chronological age of 5.4 years (RMSE: 7.2 years; Figure 3.3.8c). To further
simplify application of the Epigenetic-Aging-Signature we compiled an online calcula-
tor which implements this equation (http://www.molcell.rwth-aachen.de/epigenetic-
aging-signature/). This method was subsequently applied to an independent validation
set consisting of 69 samples. Notably, the predictions for the validation set correlated
even better with chronological age (MAD: 4.5 years; RMSE: 5.6 years; Figure 3.3.8d),
indicating that pyrosequencing of these three CpG sites yielded reliable age predictions.
80
3. Results
Figure 3.3.8: Validation of the Epigenetic-Aging-Signature.
(a) Three AR-CpG loci were analyzed by pyrosequencing, and (b) their DNAm profiles
were correlated with age. For cg17861230 (PDE4C), the correlation was even better
at a neighboring CpG locus that was therefore preferred for further analysis. (c) Age-
predictions based on these 3 CpGs revealed a relatively high precision (MAD: 5.43
years), and (d) it was validated in an independent set of 69 samples.
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3.4 Epimutations ofDNMT3AMimic Genomic Mu-
tations in Acute Myeloid Leukemia
3.4.1 DNA Methyltransferases and Acute Myeloid Leukemia
DNA methylation (DNAm) of CpG dinucleotides is a key epigenetic process (Koch
et al., 2012; Teschendorff et al., 2010). Upon cell division, the DNAm pattern is main-
tained on the newly synthesized DNA strand particularly by DNA methyltransferase
1 (DNMT1), whereas DNMT3A and DNMT3B act as de novo methyltransferases
(Okano et al., 1999). In addition, a co-regulatory methyltransferase-like protein,
DNMT3L, modulates activity of DNMT3s (Goll and Bestor, 2005; Gopalakrishnan
et al., 2009). Interestingly, all three catalytically active DNMTs are subjected to
extensive tissue or developmental stage specific alternative splicing. Different vari-
ants of DNMT3s, which have different interaction and binding properties, are even
co-expressed within the same cell (Van Emburgh and Robertson, 2011). Such alterna-
tively spliced forms of DNMTs may process altered enzymatic activity and they may
favor specific genomic regions (Robertson et al., 1999; Weisenberger et al., 2002).
DNAm plays a central role in normal hematopoietic development. Recently, there is
a growing perception that it is also crucial for dysfunctional hematopoiesis in myeloid
neoplasms. Conditional ablation of DNMT3A in mice has been shown to increase
the stem cell pool and to impair differentiation (Challen et al., 2011). The relevance
of DNMT3A is further supported by frequent mutations in acute myeloid leukemia
(AML) (Ley et al., 2013, 2010) and myelodysplastic syndromes (MDS) (Walter et al.,
2011). About 22% of AML patients harbor mutations in DNMT3A, either at the
highly recurrent position R882, or at other sites within the gene (Ley et al., 2010).
Yan et al. have recently reported that mutations in DNMT3A are associated with
alterations of DNAm and gene expression profiles (such as HOXB genes) (Yan et al.,
2011).
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Furthermore, mutations in DNMT3A are associated with a poor prognosis in AML and
have hence been suggested to be taken into consideration for risk stratification (Ley
et al., 2010; Ribeiro et al., 2012). The role of DNMT inhibitors in the treatment of
MDS and AML has been addressed in multiple clinical trials. For instance, treatment
with azacytidine resulted in a longer overall survival, a lower transfusion frequency,
and a delay of transformation from MDS into AML. However, the exact mode of action
of DNMT inhibitors is just beginning to be understand (Schermelleh et al., 2005), yet
predictive biomarkers, best schedule of administration, and combination with other
treatment modalities are still unknown (Fenaux et al., 2009).
Although it has been recognized that alternative isoforms of DNMT3s might be rel-
evant in AML, this has not been systematically addressed. In particular, little is
known how DNAm is affected within the DNMT3A gene. In some studies, it has
been proposed that such modifications may be involved in the regulation of alterna-
tive isoforms (Dolnik et al., 2012; Shukla et al., 2011). In this study, we made an
assumption that epigenetic modification within the gene DNMT3A might affect ex-
pression of variant transcripts and thereby mimic mutations in DNMT3A. To this end,
we have analyzed DNAm profiles of various publicly available data sets based on the
Illumina HumanMethylation450K BeadChip. This platform assays more than 480 000
CpG sites at single base resolution (covering 99% of RefSeq genes and 96% of CpG
islands) (Bibikova et al., 2011). We have demonstrated that DNAm profiles in AML
revealed frequent hypermethylation at an internal promoter region of DNMT3A that
was not observed in normal blood. In analogy to mutations in DNMT3A, this aberrant
hypermethylation is associated with a poor prognosis in AML. This study was done in
collaboration with Edgar Jost, Department of Oncology, Hematology and Stem Cell
Transplantation, RWTH Aachen University Medical School, Aachen, Germany and
Wolfgang Wagner, Helmholtz Institute for Biomedical Engineering, Stem Cell Biology
and Cellular Engineering, RWTH Aachen University Medical School, Aachen, Ger-
many.
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Figure 3.4.1: Variable DNAm within DNMT3A in AML.
(a) Schematic presentation of four different transcripts for DNMT3A. The positions
of corresponding CpG probes represented on the HumanMethylation450k BeadChip
platform and their relation to CpG islands are depicted. (b) Beta-values reflecting
DNAm level for each of these CpG sites were analyzed in 656 normal blood samples
(Hannum et al., 2013). Standard deviation (s.d.) of beta-values revealed relatively
little inter-individual variation at all CpG sites. (c) However, DNAm profiles of 194
AML samples (Ley et al., 2013) revealed three DMRs which are highlighted in light red.
Probe set IDs for the most prominent CpG sites are indicated by arrows. Furthermore,
locations of genomic mutations are indicated using light red vertical bars. Notably, all
mutations in DNMT3A are related to exons of transcript 2.
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3.4.2 Differentially Methylated Regions ofDNMT3A revealed
in AML Samples
The gene DNMT3A consists of 23 exons and four main transcripts, as described in
Figure 3.4.1a. A large data set with 656 blood samples of healthy donors that was
created by Hannum and co-workers (Hannum et al., 2013) revealed only little inter-
individual variation in the DNAm pattern of CpG sites related to DNMT3A (Figure
3.4.1b). In contrast, bone marrow-derived blood samples of 194 AML patients from
TCGA repository data (Ley et al., 2013) revealed three differentially methylated re-
gions (DMRs) within DNMT3A (Figure 3.4.1c; highlighted in light red background).
aberrant hypomethylation at DMR1 
DNAm at CpG site cg14189391 < 50% 
 
aberrant hypermethylation at DMR2 
DNAm at CpG site cg08485187 > 10% 
 
aberrant hypermethylation at DMR3 
DNAm at CpG site cg19489797 > 10% 
 
23 3 
62 
7 2 
97 no aberrant DNAm in DNMT3A  
Figure 3.4.2: Pie diagram for the interplay of three DMRs in DNMT3A.
DNA methylation profiles of 196 AML samples from the TCGA repository data (Ley
et al., 2013) revealed three differentially methylated regions (DMRs). Based on DNAm
in normal blood (Hannum et al., 2013), we defined cutoffs for aberrant DNAm. DMR1,
particularly at CpG site cg14189391, was always methylated more than 50% in normal
blood, whereas it was hypomethylated (DNAm< 50%) in 26 AML samples. In contrast
DMR2 and DMR3 were non-methylated in normal blood (especially at CpG sites
cg08485187 and cg19489797), whereas they were hypermethylated (DNAm > 10%) in
72 and 9 AML samples, respectively. Notably, there was very little overlap between
hypomethylation at DMR1 and hypermethylation at DMR 2 or DMR 3, i.e., three
samples and no sample shared, respectively.
In comparison to normal blood, DMR1 was hypomethylated in some AMLs. This
hypomethylation revealed rather little overlap with DNA hypermethylation that oc-
curred at DMR2 and DMR3 (Figure 3.4.2). Hypermethylation at DMR2 and DMR3
was also observed in malignant hematopoietic cell lines, whereas different subsets of
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mature hematopoietic cells displayed relatively little variation, indicating that DNAm
changes are not due to changes in cellular composition (data not shown). Notably,
DMR2 corresponded to an upstream promoter region of transcript 2 that we have re-
cently identified in hematopoietic stem and progenitor cells (HPCs). This region that
contained a CpG-island (CGI) was non-methylated in CD34+ cells from cord blood
and revealed some of the most significant hypermethylation upon culture expansion
in vitro (p-value < 10−46; Weidner et al. 2013). This led us to the assumption that
this region might be of particular relevance for maintenance of normal hematopoietic
integrity and therefore we focused on DNAm at DMR2 for further analysis.
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Figure 3.4.3: Bisulfite pyrosequencing assays of DNAm at DMR2.
DNAm at the CpG site cg08485187 (within DMR2) was analyzed by bisulfite py-
rosequencing in peripheral blood of healthy controls and patients with AML, chronic
myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV),
and myelofibrosis (MF)
To further extend our observation, bisulfite pyrosequencing assays were designed to
specifically address DNAm at DMR2 in blood of healthy controls (n = 26) and patients
with chronic myeloid leukemia (CML; n = 15), essential thrombocythemia (ET, n =
13), polycythemia vera (PV; n = 12), myelofibrosis (MF; n = 20), and AML (n = 88,
in collaboration with Wolfgang Wagner, Helmholtz Institute for Biomedical Engineer-
ing, Stem Cell Biology and Cellular Engineering, RWTH Aachen University Medical
School, Aachen, Germany). As expected, the DNAm level was always below 10% in
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controls whereas it was increased in many patients with myeloproliferative neoplasms
(MPN). Very high DNAm levels at DMR2 were exclusively found in a subset of AML
samples (Figure 3.4.3). We therefore defined epimutations to be present if the DNAm
level at the CpG site relating to probe set cg08485187 was above 10%, as this level
has not been reached in any of the controls.
3.4.3 Interplay of Epimutations and Mutations in DNMT3A
In several other tumor-associated genes, such as BRCA1 in ovarian cancer (Cancer
Genome Atlas Research Network, 2011) and CDKN2A in squamous carcinoma (Ham-
merman et al., 2012), the causal relevance of epigenetic changes has been supported by
the finding that the silencing events are mutually exclusive with mutational inactiva-
tion of the same gene (Shen and Laird, 2013). To investigate if DNA hypermethylation
at DMR2 is related to genomic mutations of DNMT3A, we further analyzed the 194
AML samples of TCGA that provided sequencing information of the entire DNMT3A
gene (Ley et al., 2013) and classified them into four categories, as reported in Figure
3.4.4a. Epimutations (i.e., epi(+)) and mutations (i.e., mut(+)) in DNMT3A ap-
peared to be vastly mutually exclusive (p-value = 0.042, hypergeometic distribution).
Specifically, only 11 AML samples had both epimutations and mutations in DNMT3A.
Furthermore, the DNAm levels within DMR2 of DNMT3A were significantly higher in
samples without genetic mutation (p-value = 0.0037, Wilcoxon rank-sum test; Figure
3.4.4b).
Patients harboring mutations were enriched in the cohorts with the intermediate or
poor cytogenetic risk as described before (p-value < 10−20, hypergeometric distribu-
tion) (Ley et al., 2013). Interestingly, patients with epimutations in DNMT3A, even in
the subset without mutations, revealed the same enrichment in intermediate or poor
cytogenetic risk groups (p-value < 0.001, Wilcoxon rank-sum test; Figure 3.4.4c) and
the same tendency was also observed in our patients (data not shown). In analogy to
DNMT3A mutations, the epimutations were not found in core binding factor (CBF)-
AMLs (defined by RUNX1-RUNX1T1 or CBFB- MYH11 fusion) and only very rarely
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Figure 3.4.4: Interplay of epimutations and mutations in DNMT3A.
(a) DNAm profiles of TCGA (Ley et al., 2013) were categorized in samples with
DNMT3A mutation (mut+) and those with aberrant DNA hypermethylation at
cg08485187 (beta-value > 0.1) that has been classified as epimutation (epi+). (b,c)
Aberrant DNA hypermethylation was significantly lower in AML samples with
DNMT3A mutations and it was hardly associated with a good cytogenetic risk score
(n.d. = not determined). (d) Analysis of RNA-sequencing data (Ley et al., 2013)
revealed that DNMT3A transcript 2 is slightly less expressed in samples with epimu-
tation (red bar) and significantly down-regulated in samples with DNMT3A mutations
(blue bar). Statistical significance was estimated by Wilcoxon rank-sum test. RPKM
= reads per kilobase per million reads.
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Figure 3.4.5: Organization of mutations in DNMT3A categories.
AML samples of TCGA (Ley et al., 2013) have been analyzed using either whole-
genome sequencing (50 cases) or whole-exome sequencing (150 cases). 194 samples
with DNAm profiles were subsequently grouped in those with epimutation (epi+)
and/or mutation (mut+) in DNMT3A and analyzed with regard to gene fusions or
mutations. A selection of relevant mutations is presented that revealed differences
in samples with DNMT3A modifications (black depicts mutation or epimutation of
corresponding genes). For clarity, other mutations are not shown. Notably, MYH11-
CBFB, RUNX1-RUNX1T1 and PML-PARA fusions were significantly enriched in epi(-
)mut(-) samples (p-value < 0.001, p-value = 0.009, and p-value < 0.001, respectively;
chi-squared test). These fusions have been associated with good prognosis. In contrast,
the frequent mutations in NPM1, IDH1, IDH2 and RUNX1 were significantly enriched
in patients with mutations and/or epimutations in DNMT3A (p-value < 0.001, p-value
< 0.001, p-value < 0.001, and p-value < 0.027, respectively; the color code on the top
corresponds to DNMT3A modifications according to Figure 3.4.4a).
in acute promyelocytic leukemia (PML-PARA fusion) (Jourdan et al., 2013). On the
other hand, mutations as well as epimutations in DNMT3A were significantly associ-
ated with mutations of IDH1, IDH2, RUNX1 and NPM1 (Figure 3.4.5).
Hypermethylation at DMR2 and DMR3 that seem to be related to the internal pro-
moter region of transcript 2 may result in down-regulation of DNMT3A transcript
2. The analysis of RNA-sequencing data of TCGA (Ley et al., 2013) revealed that
particularly those exons present in transcript 2 were highly expressed in AML samples
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Figure 3.4.6: Expression of DNMT3A transcripts.
(a) Transcription of exons were analyzed in RNA-sequencing data of TCGA (Ley et al.,
2013). The scheme depicts which exons are comprised in the four main transcripts of
DNMT3A (alternative exons included in variant transcripts are indicated by letters;
U = undefined transcript association). In samples with aberrant hypermethylation
in DMR2 (DNAm > 10% at cg08485187) particularly exons involved in transcript 2
were slightly less expressed than in patients without epimutation (RPKM = reads per
kilobase per million reads). (b) Notably, these exons revealed an even more pronounced
down-regulation in samples with DNMT3A mutation (** p-value < 0.01; *** p-value <
0.001; two-sided t-test). (c) To further analyze if the epimutation and mutation have
impact on the relative expression of variant transcripts we used quantile normalization
to scale the expression levels of four transcripts to same level. Expression levels of
individual transcripts were then normalized to transcript 1. The analysis revealed that
transcript 2 and transcript 4 are relatively less expressed in AML with epimutation in
DNMT3A (Wilcoxon rank-sum test).
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(Figure 3.4.4d). Interestingly, these exons were rather lowly expressed in patients with
epimutation (Figure 3.4.6a). Due to the high inter-individual variation in DNMT3A
expression, we have determined relative expression as compared to transcript 1. In fact,
transcript 2 was then slightly less expressed in patients with epimutation in DNMT3A
(p-value = 0.026). Unexpectedly, an even more pronounced down-regulation of tran-
script 2 was observed in patients with mutations in DNMT3A (Figure 3.4.4d), even
though the frequently mutated exon 23 is usually also part of transcripts 1 and 3. In
this regard, it is also interesting that all genomic mutations in DNMT3A described in
TCGA data were associated with exons of transcript 2 - but not with DMR2 or DMR3
directly (Figure 3.4.1c). Taken together, both epimutations and mutations resulted in
down-regulating the relative expression of DNMT3A transcript 2.
3.4.4 DNAm and Gene Expression Changes Associated with
DNMT3A Epimutations
Next, we analyzed if the DNMT3A epimutation would yield a positive or negative
correlation with DNAm changes. A total of 3,536 CpGs revealed significant DNAm
changes (samples with DNMT3A mutation were excluded for this comparison). No-
tably, almost the entire set (i.e., 3,523 CpGs) was hypermethylated in samples with
DNMT3A epimutation. In contrast, comparison of DNAm profiles of AMLs with
DNMT3A mutation versus wild type AMLs (both without epimutation) revealed
that only 78 CpGs were significantly hypermethylated, whereas 2,595 CpGs were hy-
pomethylated in mutated samples and many of them were associated with homeobox
genes, including HOXA2, A6, A7, A9, B2, B3, B4, and B8. The association of differ-
ential DNAm in samples with either mutation or epimutation was relatively moderate.
However, overall there seemed to be a significant relationship (p-value = 0.0005, chi-
squared test; Figure 3.4.7).
Furthermore, epimutated (red) and mutated samples (blue) were grouped together
for comparison with samples without DNMT3A modifications (green). We detected
444 CpGs as differentially methylated (Figure 3.4.8a, b), indicating 369 hypermethy-
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Figure 3.4.7: Correlation of differential DNAm in patients with either
epimutation or mutation.
Differential DNAm levels in patients with or without epimutation (i.e., x-axis) were
plotted against differential DNAm levels in patients with or without mutation (i.e.,
y-axis). CpG sites with absolute difference in DNAm level of more than 20% in both
comparisons are depicted in black. The corresponding number of CpG sites in these
four regions is provided. Chi-square analysis of these CpG sites indicated that there
is a significant relationship between the two comparisons (p-value = 0.0005).
lated and 75 hypormethylated CpG sites. These results revealed some concordance in
DNAm changes upon either epimutation or mutation of DNMT3A. The overlapping
hypomethylation that induced by epimuation and mutation was associated with sev-
eral homeobox genes, for instance, HOXA9 shown in Figure 3.4.9.
We have then analyzed if DNAm changes in AML with DNMT3A epimutation are
also reflected on gene expression level. RNA-sequencing data from the TCGA (Ley
et al., 2013) revealed that 205 genes were differentially expressed in AML samples with
or without DNMT3A epimutation (samples with DNMT3A mutation were excluded
from this comparison). In total, 81 genes were significantly down-regulated whereas
124 genes were up-regulated, the latter including HOXA1, A2, A3, A4, A5, A6, A7,
A9, A10, B3, B4, B5, and B6. Chemical and Genetic Perturbations (CGP) demon-
strated most significant association of up-regulated genes with three datasets of AML
mutations in NPM1 (Alcalay et al., 2005; Mullighan et al., 2007; Verhaak et al., 2005)
(p-values always < 10−16) that might point to an association of DNMT3A epimutation
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Figure 3.4.8: DNAm changes in samples with epimutation/mutation in
DNMT3A.
(a) Heat map of 444 CpGs with significant DNAm changes between samples with
epimutation and/or mutation in comparison to AML samples without such DNMT3A
modifications (adjusted p-value < 0.05; differential DNAm > 20%). (b) The box plots
of average DNAm levels (beta-values) of the CpG sites that were either hypermethy-
lated or hypomethylated indicated in a.
with NPM1 mutation as mentioned above. Furthermore, differentially expressed genes
were also found to be up-regulated in HPCs upon overexpression of NUP98-HOXA9
fusion protein (p-value < 10−16) (Takeda et al., 2006).
As an example, HOXA9 was significantly up-regulated in both categories of DNMT3A
modifications and this has been associated with poor prognosis in AML before (Figure
3.4.9) (Hayette et al., 2012). In fact, almost the entire HOXA and HOXB cluster
were significantly up-regulated in AML samples with either epimutation or mutation
in DNMT3A (Figure 3.4.10). The clear correlation of differentially expressed genes
indicates that the molecular consequences of epimutation and mutation in DNMT3A
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might be related.
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Figure 3.4.9: DNAm and expression changes of HOXA9 in samples with
epimutation/mutation in DNMT3A.
(a) DNAm pattern of CpG sites related to the gene HOXA9 is exemplarily depicted.
AML samples with either mutations or epimutations in DNMT3A revealed significantly
lower DNAm levels. (b) Conversely, HOXA9 shown a significantly higher expression
in samples with DNMT3A mutation or epimutation. Statistical significance was esti-
mated by Wilcoxon rank-sum test.
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Figure 3.4.10: Comparison of gene expression changes induced by epimu-
tation and mutation in DNMT3A.
Differential gene expression in AML samples with or without epimutation (i.e., x-axis)
was plotted against differential gene expression in AML samples with or without ge-
nomic mutation in DNMT3A (i.e., y-axis). Genes with differential expression in either
one or both comparisons are highlighted in black and red, respectively. The correlation
coefficient between black or red data points is also provided, respectively. Gene IDs
are provided for genes significant in both comparisons.
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3. Results
3.4.5 DNMT3A Epimutations are Associated with Poor Prog-
nosis
Finally, we analyzed the impact of DNMT3A epimutations on clinical prognosis. Pa-
tients with DNMT3A mutations (mut+) revealed a significantly shorter event-free sur-
vival (EFS) than patients without mutation (mut-) in TCGA (Ley et al., 2013). This
observation was in line with previous studies (Ley et al., 2010; Yan et al., 2011) that
showed mutations in DNMT3A are related to poor prognosis. In analogy, patients with
epimutation (epi+) revealed a significantly shorter EFS than those without epimuta-
tion (epi-) (Figure 3.4.11). These results support the notion that epimutations in
DNMT3A, same as genomic mutations (Ley et al., 2010; Marcucci et al., 2012; Ribeiro
et al., 2012), are rather associated with poor risk score and poor prognosis in AML.
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Figure 3.4.11: Kaplan-Meier analysis of event-free survival of individuals
with AML.
(a) Kaplan-Meier plot for AML patients with DNMT3A mutations (mut+; 49 patients)
and without mutation (mut-; 145 patients). (b) These 145 patients without mutation
were subdivided into two subsets with (epi+) and without epimuation (epi-) as shown
in Figure 3.4.4a. Kaplan-Meier plot for these two subsets of patients is shown. In each
plot, p-value and median EFS is provided. In collaboration with Dr. med. Stefan
Wilop, Dr. med. Edgar Jost, Department of Oncology, Hematology and Stem Cell
Transplantation, RWTH Aachen University Medical School, Aachen, Germany
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Chapter 4
Discussions and Conclusions
Haematopoiesis, the development of multipotent hematopoietic stem cells into termi-
nally differentiated blood cells, is know to be governed by a tightly control of gene
expression programs (Ceredig et al., 2009; Doulatov et al., 2012). This complex regu-
lations of transcription that drive lineage fate determination not only rely on transcrip-
tional factor networks, but also on the epigenetic landscape (i.e., chromatin states) of
the cells (Sashida and Iwama, 2012). Recent advances in the high-throughput tech-
nologies, such as microarray and next generation sequencing, provide excellent means
to comprehensively study the dynamics of transcriptional programs and their regula-
tion during lineage restriction and differentiation.
The cells in hematopoietic system, including DC, are repopulated continuously from
bone marrow-derived stem and progenitor cells. Due the heterogeneity of DC, the
fate determination of DC lineage and the relationship between DC subsets and their
progenitors remain under investigation. In this thesis, to investigate the underlying
molecular mechanism of DC differentiation, we performed a global transcriptome anal-
ysis upon DC differentiation from hematopoietic stem cell to two major DC subsets.
The clustering analysis of differentially regulated genes upon DC differentiation identi-
fied the underlying transcriptional programs that drives DC lineage commitment and
specification. A publicly available microarray data set that generated from in vivo
cultured hematopoietic progenitors and DC subsets were utilized to evaluate these
identified transcriptional programs, suggesting the robustness of our gene signatures.
The repression of “stem cell” gene repertoire and the activation of DC lineage-affiliated
gene signatures upon DC development reflected the restriction of lineage options in
MPP and the establishment of a DC developmental pathway.
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Many known and novel DC developmental regulators were further identified, such as
Irf4, Irf8, Batf3, Id2, Zbtb46 and Tcf4 (Belz and Nutt, 2012). Our identification of
Tcf4 as pDC marker is very much in line with the previous observation that pDC
absolutely rely on the expression of E protein E2-2 (encoded by Tcf4, Cisse et al.
2008). The E protein antagonist Id2 was also observed and considered as cDC marker,
which in consistent with the fact that the Id2-deficient mice increased pDC frequencies
(Hacker et al., 2003). Moreover, it was also recently observed that Zbtb46 expression
distinguishes cDC from other mononuclear phagocyte lineages (Satpathy et al., 2012).
Recent studies showed that CDP are DC lineage-specific progenitors that do not give
rise to any other types (Naik et al., 2007; Onai et al., 2007). An interesting phe-
nomenon was observed by analyzing transcription dynamics, showing that CDP ac-
quired an DC-primed gene expression profile. During DC commitment, the expression
of stem cell related genes was rapidly repressed in CDP, indicating the restriction of
developmental options. In contrast, the expression of DC regulators were increased
from MPP to CDP and were further enhanced in DC, reflecting the commitment of DC
lineages. These results are in consistent with the fact that CDP is a direct DC lineage-
committed progenitor cell. TGF-β1 signalling has been demonstrated to regulate DC
development by inducing the expression of DC related genes such as Id2 (Hacker et al.,
2003). The microarray data analysis on the basis of TGF-β1 treated CDP revealed
that 24h TGF-β1 treatment was sufficient to induce DC functional related genes, such
as MHC-II genes, and genes involved in Ag processing and presentation (Ctss, CD74
and H2-DMa). In addition, a cDC affiliated transcription profile was observed in 24h
TGF-β1 treated CDP, suggesting that TGF-β1 acts on DC bifurcation point and pro-
moted cDC differentiation.
It is known that the complex gene expression programs are governed by the epige-
netic landscape of chromatin. For example, the chromatin states of H3K4me3 and
H3K27me3 can effectively discriminate genes that are expressed, poised for expres-
sion, or repressed (Mikkelsen et al., 2007). Epigenetic chromatin states are proposed
to play an important regulatory role in hematopoietic lineage fate decision. The devel-
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opmental plasticity of hematopoietic stem cells was also shown to be uniquely defined
by epigenetic signatures (Weishaupt et al., 2010).
In this thesis, to investigate the molecular regulatory mechanisms underlying dendritic
cell differentiation, a genome-wide chromatin map of H3K4me3, H3K9me3, H3K27me3
was generated by ChIP-seq for MPP, CDP, cDC and pDC. The correlations between
histone modifications and transcription activity in hematopoietic stem/progenitor cells
and DC lineages suggested the positive role of H3K4me3 and the negative influence
of H3K27me3 in gene expression, which was in consistent with previous observations
in other cell types (Bernstein et al., 2006; Wei et al., 2009). In contrast to known
inhibition function of H3K9me3, our analysis suggested that H3K9me3 may play a
positive role in transcription activity upon DC development.
The comprehensive analysis of chromatin states across DC development indicated that
DC lineage-specific transcription programmes were controlled by the dynamics of epi-
genetic signatures. Many early hematopoietic factors (e.g., Gfi1, Cebpa and Gata2)
and DC genes (Flt3, Id2, Irf8 and Tcf4) were observed to be tightly regulated by
H3K4me3, H3K27me3 or bivalent modifications. Particularly, early developmental-
related genes that were uniquely bivalent modified in MPP were resolved to mono-
valent or no modification in CDP, leading to the repression of “stem cell” related
transcription program and lineage-restriction in CDP. On the other hand, the gain of
H3K4me3 marks on DC related genes activated a DC-primed expression profiles in
CDP, resulting in DC lineage commitment. These result are in line with the previous
observation the DC-primed transcription patterns in CDP.
DC development comprises lineage commitment and DC subset specifications. This
multistep developmental pathway have been demonstrated to be regulated by many
transcription factor and cytokines. For example, PU.1 was shown to control DC
development by mediating Flt3 cytokine receptor expression (Carotta et al., 2010).
However, how DC regulators coordinated as an integrative network to drive the lin-
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eage differentiation remains to be investigated.
To elucidate the transcription regulatory network of DC development, we designed
an integrative computational approach to analyze genome-wide PU.1 binding profiles
and gene expression data in MPP, CDP, cDC and pDC. On the basis of our approach,
20 transcription factors (including PU.1) were identified as PU.1 co-binding partners,
including many key DC regulators such as Irf family genes (i.e., Irf1, Irf4, Irf5 and
Irf8), Klf4, Spib and Tcf4 (E2-2). Accordingly, four lineage-specific transcription fac-
tor regulatory networks and an integrative DC regulatory circuitry were constructed
reflecting the interplay of DC regulators in each of DC developmental stages. PU.1
showed a prominent role in both DC commitment and specifications. In particular,
different sets of regulators was observed to cooperated with PU.1 in order to direct
CDP toward cDC and pDC, such as Irf4, Rel/Nfkb, Fos/Jun/Batf3 and Id2 for cDC
or Tcf4, Ets1, Irf4 and Spib for pDC. Our analysis shed lights on the basic architecture
of DC transcription regulatory programme during DC development. It also provides
a comprehensive characterization of interplay between individual key DC regulators
in each developmental stage, which may help us to further elucidate the dynamics of
DC regulators upon DC development.
DNA methylation is one important mechanism of epigenetic regulation. It plays a
critical role for hematopoietic differentiation and aging of organisms (Koch and Wag-
ner, 2011; Maegawa et al., 2010). DNA methylation is also well known to change
upon aging (Fraga and Esteller, 2007). It has been shown that age-related CpG sites
enable the prediction of human chronological age (Bocklandt et al., 2011; Hannum
et al., 2013). However, these studies were based on Illumina BeadChip technology, a
method which requires complex bioinformatic analysis. In this study, we addressed
the question if an assay based on bisulfite pyrosequencing of few CpG sites might be
a more efficient and user-friendly approach with similar accuracy as DNAm profiling
approaches. To this end, we collected publicly available DNAm profiles of blood sam-
ples to identify age-related CpG sites which may relate best to predict donor age.
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In this thesis, we have performed a comprehensive analysis on a large repertoire of
DNAm profiles to narrow down 102 age-related CpG sites in blood. A method was
subsequently proposed to derive a multivariate linear model for age prediction in blood
samples on the basis of DNAm at three specific CpG sites. This model was based on
locus specific pyrosequencing analysis of bisulfite-converted DNA, i.e., an approach
that is relatively cost effective and does not require complicated bioinformatics. Most
importantly, the precision of our method was much better than alternative approaches,
such as measurement of telomere length, DNA rearrangements or protein alterations
(Meissner and Ritz-Timme, 2010). This assay can be used for forensic analysis of blood
samples. Theoretically it can be scaled down for relatively small traces of blood. In
addition, it may also be useful to uncover interchange of blood samples. Furthermore,
our method may facilitate the estimation of biological age in blood. Such predictions
would be useful for geriatric assessment and help tailor life style to improve the odds
of staying healthy.
Age-related DNAm changes were suggested to be a tissue-specific phenomenon (Mae-
gawa et al., 2010; Thompson et al., 2010). However, we and other authors demon-
strated, that similar but not identical, DNAm changes are acquired in different tissues
(Hannum et al., 2013). The Epigenetic-Aging-Signature (i.e., specific CpG sites on
ITGA2B, PDE4C and ASPA) described here has been specifically designed for blood
that is promising for practical diagnostics. Another advantage is that DNA is rela-
tively stable and can be shipped at room temperature. Notably, this method even
facilitated age-predictions in samples that have been cryopreserved for more than 10
years.
It still remains unclear if and how AR-DNAm changes are controlled. Our analysis
suggests that AR-DNAm changes are rather due to the loss of DNAm-maintenance
at specific regions. In particular, hypermethylation happens in regions which are as-
sociated with repressive histone marks and polycomb group protein targets, whereas
hypomethylation may be enriched with other histone modifications, TF binding sites
or chromatin organizations (Rakyan et al., 2010; Teschendorff et al., 2010). However,
100
whether AR-DNAm changes are cause or consequence of aging needs to be further
elucidated.
Epimutation (i.e., hyper or hypomethylation) defined heritable changes in gene activity
are not due to changes in DNA. These epimuation occur in somatic cells, particularly
in tumor suppressor genes. Recently, there is a growing perception that the abnor-
mal DNAm may play a critical role in regulation of both normal and dysfunctional
hematopoiesis. For instance, particular CpG sites that were non-methylated in CD34+
cells from cord blood were significantly hypermethylated upon culture expansion in
vitro (Weidner et al., 2013). In this thesis, we described that AML patients often
reveal aberrant hypermethylation in DNMT3A and the same effect was also observed
in AML cell lines. We also observed that the epimutation is associated with signifi-
cantly down-regulation of relative expression of DNMT3A transcript 2. Unexpectedly,
a much more pronounced down-regulation of transcript 2 was observed in samples with
genomic mutations in DNMT3A.
Global DNA methylation profiling analysis revealed that DNAm at several CpG sites
was regulated in a similar fashion by mutation and epimuation. Furthermore, there
was a significant overlap of differentially expressed genes that were induced by both
modifications, such as HOX family genes. Extensive up-regulation of HOXA7 and
HOXB2, B3, B4, B5, B6, B7, and B8 has been demonstrated before in AML samples
with mutation in DNMT3A (Yan et al., 2011). In analogy, many genes of the HOXA
and HOXB cluster were up-regulated in samples with an epimutation in DNMT3A.
Additionally, epimutations and mutations in DNMT3A were found to be enriched
in AML samples with an intermediate or poor cytogenetic risk. Further analysis of
AML samples in TCGA data revealed that both modifications are associated with
significantly shorter EFS. Taken together, we concluded that epimuation in DNMT3A
mimics the genomic mutation in AML patients and associates with poor risk score and
poor prognosis.
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